

University of Dundee

Viral etiology and the impact of co-detection in young children presenting with influenza-like illness

Lim, Faye J.; Wake, Zoe V.; Levy, Avram; Tempone, Simone; Moore, Hannah C.; Richmond, Peter C.

Published in:
Journal of the Pediatric Infectious Disease Society

DOI:
[10.1093/jpids/piw042](https://doi.org/10.1093/jpids/piw042)

Publication date:
2016

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Lim, F. J., Wake, Z. V., Levy, A., Tempone, S., Moore, H. C., Richmond, P. C., de Klerk, N., Conway, N., Keil, A. D., Effler, P. V., Smith, D. W., & Blyth, C. C. (2016). Viral etiology and the impact of co-detection in young children presenting with influenza-like illness. *Journal of the Pediatric Infectious Disease Society*, 6(3), 260-266. [piw042]. <https://doi.org/10.1093/jpids/piw042>


General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Viral etiology and the impact of co-detection in young children presenting with influenza-like illness

Journal:	<i>Journal of the Pediatric Infectious Diseases Society</i>
Manuscript ID	JPIDS-2016-025.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Lim, Faye; Telethon Kids Institute, The University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases Wake, Zoe; Princess Margaret Hospital for Children, Department of General Paediatrics; Princess Margaret Hospital, Department of Infectious Diseases Levy, Avram; PathWest Laboratory Medicine Western Australia, QEII Medical Centre; University of Western Australia, School of Pathology and Laboratory Medicine Tempone, Simone; PathWest Laboratory Medicine Western Australia, QEII Medical Centre Moore, Hannah; Telethon Kids Institute, The University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases Richmond, Peter; Telethon Kids Institute, The University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases; Princess Margaret Hospital for Children, Department of General Paediatrics; University of Western Australia, School of Paediatrics and Child Health de Klerk, Nicholas; Telethon Kids Institute, The University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases Conway, Nicholas; University of Dundee, Medical Education Institute Keil, Anthony; Princess Margaret Hospital for Children, g. Department of Microbiology, PathWest Laboratory Medicine Effler, Paul; Department of Health, Communicable Disease Control Directorate Smith, David; QEII Medical Centre, PathWest Laboratory Medicine WA; University of Western Australia, School of Pathology and Laboratory Medicine Blyth, Christopher; University of Western Australia, School of Paediatrics and Child Health; Princess Margaret Hospital, Department of Infectious Diseases; Telethon Kids Institute, The University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases; Princess Margaret Hospital for Children, Department of Microbiology, PathWest Laboratory Medicine WA</p>
Keywords:	Respiratory infection, Viral infection, Child, Co-detection

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For Review Only

1
2
3 **Please note: Reviewer comments are italics with authors' response in standard font.**
4 **Corresponding page numbers are applicable to the revised manuscript with all track changed**
5 **accepted.**
6

7 **Reviewer 1 comments**

9 *Abstract*

10 *Suggest clarify that the study was restricted to influenza seasons, and describe the setting were*
11 *children were seen and samples collected.*

13 **Response**

14 Information on the restrictions on enrolment, study setting and samples collected were amended in
15 the abstract (p.5).

16
17 *Please double check calculations as some appear to be a little off – this may be due to some rounding*
18 *or observations with missing values but this is not clear in the results section (see additional*
19 *comments below).*

21 **Response**

22 As the reviewer has suggested, the differences in the presented results in the Abstract were due to
23 rounding. To minimise confusion, we have amended the abstract to report results up to 1 decimal
24 place as appropriate (pp.5-6).

25
26 *The calculation of the predicted probabilities from the logistic regression model needs to be clearly*
27 *described in the methods section. Whether the predicted probability for flu + RSV is significantly*
28 *higher than others need to be clarified as well.*

29 **Response**

30 We have clarified this in the abstract of the revised manuscript (pp.5-6).

32 *Introduction*

33 *Suggest reconcile description of study settings with information from methods, as apparently not all*
34 *recruitments were done at the emergency department*

36 **Response**

37 To simplify analyses and minimise confusion regarding the study setting, we have chosen to exclude
38 children enrolled from general practises in the revised manuscript. Only 131 were recruited from
39 general practice in 2008-2009 before this arm of the study was stopped. All children included in the
40 analyses were enrolled while they were transiting through the emergency department. A portion of
41 these children would subsequently have been admitted as inpatients. We have included additional
42 information on the timing and location of enrolment in the Introduction (p.7) with further
43 information included in the Methods section (p.8). The number of patients excluded from general
44 practice are included in the Results section (p.12).

46 *Methods*

47 *Settings and participants*

48 *Suggest clarify how the influenza seasons were defined, based on calendar week/month?, laboratory*
49 *surveillance?, etc.*

51 **Response**

52 The start and end of influenza seasons were defined by the Infectious Diseases Surveillance Unit at
53 PathWest Laboratory Medicine WA using a combination of indicators, including weekly proportion of
54 laboratory influenza tests positive. As a guide, two consecutive weeks with over 10% influenza test
55 positive often coincides with the beginning of influenza season in WA. The manuscript has been
56 amended to include additional information on how influenza seasons were defined (p.8).

1
2
3 Clarify the different settings that were used for enrolment by season, and describe the distribution of
4 these patients in results (e.g. % of children enrolled from inpatient facilities, etc.). How were
5 hospitalized children treated in the analysis, for example in the assessment of risk of hospitalization?

6 **Response**

7 We acknowledge the confusion in the distribution of enrolment settings and consequently have
8 opted to exclude data from all children enrolled at general practises (see response to Introduction
9 comments above). All children presented to the emergency department of a single hospital and
10 were either admitted or discharged home. Hospital admission was a key outcome of interest.

11
12
13 How was influenza vaccination data collected? What proportion of self-report was verified? What
14 proportion of children were fully vaccinated?

15 **Response**

16 Vaccination data were collected through parental-report and confirmed through the Australian
17 Childhood Immunisation Register. If there was ongoing uncertainty, immunisation providers were
18 contacted. Data on vaccination status (apart from influenza vaccination) were not collected. The
19 manuscript has been amended to include this information (p.9).

20
21 Was antiviral use before sample collection measured or accounted for in the analyses?

22 **Response**

23 Only data on antiviral use post-enrolment were collected as part of the follow-up questionnaire.
24 However, only 9 patients were prescribed anti-viral medications and as such, data on anti-viral
25 medications were not included in the analyses.

26
27 *Respiratory virus detection*

28 Several tests are described for different viruses but it is unclear if testing was systematic throughout
29 the study period or some changes in testing were implemented over time. This seems very crucial as
30 not all the described tests may have similar performance for viral detections. This information needs
31 to be clearly described in the methods section.

32 **Response**

33 Testing was consistent throughout the study with all patients undergoing the same panel of tests
34 with the only exception being testing for human metapneumovirus (hMPV). References detailing the
35 PCR assays designed and validated specifically for this study have been included in the manuscript
36 (reference #14-16). Testing for hMPV was based on clinical need. In addition, during the lifetime of
37 the study, a PCR assay for hMPV was designed and implemented, gradually replacing the previously
38 utilised antigen detection assay. Although infrequently detected, we have elected to include samples
39 using both hMPV assays given the importance of this pathogen. This information has been included
40 in the Methods section (p.10) and we have also acknowledged the limitations of using two assays in
41 the Discussion section (p. 16).

42
43 Also, please clarify if all samples were tested for all study viruses – this is important to confirm that
44 samples had equal chance of having co-detections identified.

45 **Response**

46 All samples were tested for all study viruses (see response above).

47
48 Was influenza and parainfluenza combined for all analyses? Suggest clarify the rationale for this
49 decision – if this is the case then the abstract, discussion and conclusions need to be revised
50 accordingly.

51 **Response**

52 Influenza virus subtypes (i.e. Influenza A, B and C) were grouped together. Likewise, subtypes of
53 parainfluenza (i.e. parainfluenza types 1-4) were grouped together. Influenza and parainfluenza
54 were treated as separate groups. This point has been clarified in the Methods section (p. 10).

1
2
3
4 *Definitions and statistical analysis*

5 *Clarify how the children enrolled in the inpatient setting were considered for the study of*
6 *hospitalization as an outcome.*

7 **Response**

8 As all children transited through the emergency department, all children were treated in the same
9 manner in the regression model with hospitalisation as the outcome measure.

10
11 *How was age (covariate) accounted for in the regression models? The table shows data as a*
12 *categorical variable but use of age as a continuous variable is warranted to minimize residual*
13 *confounding.*

14 **Response**

15 In the original manuscript, age was included in the model as a categorical variable with 5 subgroups
16 (i.e. 6-11 months, 12-23 months, 2 years, 3 years and 4 years). We have since re-assessed models
17 that include age as a continuous variable and found no difference in the model fit whether age was
18 used as a continuous or categorical variable. As such, we have chosen to retain age as a categorical
19 variable for the easier interpretation of the results. We have amended the manuscript to explicitly
20 state this in Method sections (p.11) and as footnotes in Table 2.

21
22 *Suggest clarify the models were used to calculate 'predicted' probabilities – it is important to provide*
23 *details about model building strategies, as the estimated probabilities depend heavily on the model*
24 *structure. Suggest consider influenza vaccination history before enrolment, antiviral use, duration of*
25 *disease (from onset to testing), enrolment setting and respiratory season as additional covariates for*
26 *the regression models. If additional information is available about presence of young children at*
27 *home, that would be another covariate of interest.*

28 **Response**

29 We acknowledge that the addition of the suggested covariates would help to strengthen the models.
30 We have attempted to include these additional covariates into the models but found that this
31 greatly reduces the number of cases contributing data to the model due to missing data.
32 Comparisons, using the likelihood ratio test of standardised sample size, of the logistic regression
33 model of hospitalisation with all the additional covariates requested showed no significant
34 differences in model fit compared to the restricted model with only the covariates listed in the
35 original manuscript. Inclusion of all requested covariates also resulted in quasi-separation of the
36 data, which limited our ability to perform the post-hoc analyses used to produce Figures 2 and 3.

37
38 As such, we have decided to retain the covariates used in the original model. We have also included
39 additional information on the model building strategies used in the Methods section of the revised
40 manuscript (p.11).
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Results*

4 *How many seasons were included in the study? Was the pandemic year distinct enough, so that it*
5 *may warrant a sensitivity analysis excluding it from the main analysis?*

6 **Response**

7 Influenza seasons from 2008 to 2012 (i.e. total of 5 influenza seasons) were included in this analyses.
8 Given the questionable impact of co-detection is relevant in both pandemic and seasonal influenza
9 seasons, we have kept the 2009 season in the analysis. While we acknowledge that it would be
10 interesting to perform a sensitivity analyses excluding data from the pandemic year (2009), we feel
11 that this would be outside the scope of this study. Furthermore, excluding data from this year would
12 likely limit our ability to assess the effects of specific virus pairs given the limited sample size.
13

14 *Clarify what proportion of children had comorbidities.*

15 **Response**

16 The manuscript has been amended to include this information (p.11).
17

18 *Suggest clarify whether the described antibiotic use refers to the enrollment event or the follow-up*
19 *questionnaire?*

20 **Response**

21 Data on antibiotic use was collected in the follow-up questionnaire. We have amended the
22 manuscript to explicitly state that it refers to antibiotic use post-enrolment (p.12).
23

24 *How many children had completed the follow-up questionnaire? It seems that the outcomes would*
25 *be only known for those who completed it but cannot tell from the description. The proportion*
26 *described with antibiotic data (52.6%) is very different from the proportion with hospitalization data*
27 *(99%). The methods indicate that medical records review were done for hospitalizations but it is*
28 *unclear whether antibiotic information was reviewed as well. This is very important as this*
29 *potentially modify the n for some of the analyses.*

30 **Response**

31 Of 2356 patients, 52.8% (n=1244) completed questions relating to outcomes (e.g. antibiotics use).
32 Information on antibiotics data were not reviewed beyond data collected via questionnaire as the
33 majority of patients were discharged from the emergency department and therefore, may not have
34 adequate information recorded on subsequent antibiotic use. This information has been included in
35 the Methods (p.9) and Results sections (p.12) of the amended manuscript.
36

37 *Please double check the odds ratio calculations, for example in table 2 it seems that the crude odds*
38 *ratio for cough should be 1.8? Currently shown as 2.01 – similar concern for next row [rhinorrhea],*
39 *this might be a rounding issue but please verify. If there were children missing information in some of*
40 *the variables listed in the table, it would be useful to clarify that as well. Suggest add variables*
41 *included for adjustment in a footnote for Table 2.*

42 **Response**

43 The discrepancies were due to cases with missing data counted as not having a particular symptom
44 or outcome, as the reviewer suggested. To clarify this, we have included the number of children with
45 missing data for each of the symptoms and outcomes as a note in Table 2. The variables included in
46 the adjusted models have been noted in the footnotes. Please note that the values presented in the
47 revised manuscript may differ from the original manuscript due to the exclusion of children recruited
48 from general practises.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Although predicted probabilities are shown in figures 2 and 3, these come from the regression*
4 *models and it is unclear whether the described comparisons indicated significant differences or*
5 *whether chance could not be ruled out – this needs to be clarified carefully, and description of results*
6 *and discussion revised accordingly, if necessary.*

7 **Response**

8 We have amended the Methods (p.11), Results (pp.13-14) and Discussion sections (p.14) concerning
9 these results to clarify this point. Figures 2 and 3 also include 95% confidence intervals to minimise
10 the risk of over-interpretation.

11
12 *Besides the described symptoms, it would helpful to show the distribution of actual medical*
13 *diagnoses that these children received. For example were co-detections more often seen in children*
14 *with diagnosis of otitis media or pneumonia? I think this is a very important part and needs to be*
15 *added to the report.*

16 **Response**

17 We acknowledge that discharge diagnosis would have added to the analyses presented in this
18 manuscript. Unfortunately, data on the diagnoses received at discharge were not collected for this
19 study. This point has been added as a potential limitation of this study in the Discussion section of
20 the manuscript (p. 16).

21
22 *Also, children may present with more than 1 symptom, but it is not clear how those were treated in*
23 *the analyses, please clarify.*

24 **Response**

25 We have interpreted this comment to mean that the reviewer is concerned about counting the same
26 person contributing more than 1 data point in a model (i.e. if they had more than 1 symptom). As
27 each symptom and outcome was treated as a separate model, the same child could present with
28 more than 1 symptoms but will only be counted once in a particular model.

29 **Discussion**

30 *Suggest clarify if described predicted probabilities were significantly higher than other groups to*
31 *support statement in first paragraph.*

32 **Response**

33 The predicted probability of hospitalisation for those with influenza and RSV co-detections were
34 higher compared to those with influenza virus infection only with a trend observed compared with
35 RSV virus infection only. To avoid confusion, we have clarified this point in the first paragraph of the
36 Discussion section (p.14).

37
38 *The description of the post-hoc power calculation is very confusing, what is the difference of interest*
39 *for the calculation? Since the sample size is already fixed (this is a retrospective assessment), I am not*
40 *sure how useful a power estimate is – the lack of precision can be appreciated directly by the width of*
41 *the estimated confidence intervals. Suggest delete the power calculation description.*

42 **Response**

43 The power calculations were provided to suggest the numbers required to detect differences
44 between influenza and rhinovirus should a reader wish to do so in a future study. We acknowledge
45 that this can be confusing and have deleted this description from the Discussion.

46
47 *MPV detections were the lowest of all detections. How does the MPV % detections compare to other*
48 *studies? Please discuss potential reasons for discrepancies.*

49 **Response**

50 hMPV detections in this cohort was 1.0% (26/2487), which is lower than those shown in other
51 studies (approximately 5-13% for this age group). This could be partly due to lower sensitivity of
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

immunofluorescence in comparison to PCR when detecting hMPV. This information has been included in the Discussion section of the revised manuscript (p.16).

For Review Only

Reviewer 2 comments

In general, I would dissuade the frequent use of “co-infection” and favor “co-detection,” since this is largely a description of molecular detection of viruses and many of the positives (such as for rhinoviruses, in particular) may represent detection of viruses that reflect prolonged shedding in the nasopharynx but not current active infection. “Coinfection” is defined in the introduction, but I would still recommend that the authors use “co-detection” more frequently when describing results and conclusions.

Response

We acknowledge that we cannot distinguish between active infection and viral shedding and have changed the term “coinfection” to “co-detection” in the manuscript. We would refrain from using both terms within the same manuscript so as to not confuse the reader. We have also added further comments acknowledging the role of viral shedding in the Discussion section of the manuscript (p.16).

The abstract notes that rhinovirus (40%), influenza (29%), and RSV (27%) were the most commonly detected viruses. Please also present these percentages in the Results section and be clear that these are out of the 1728 with a virus detected (not of the 2487 eligible patients).

Response

Both the abstract (p.5) and Results section (p.16) has been amended to include this information.

The abstract notes that nasal swabs were tested, but the Methods section says a nasopharyngeal swab or aspirate was collected at enrollment. Please be specific as to what was routinely collected – was it nasal swab or aspirate? Was specimen type collected at clinician discretion? Were the swabs anterior nasal, mid-turbinate, or nasopharyngeal?

Response

Bilateral mid-turbinate nasal swabs (Copan Diagnostics, Murrieta, CA) placed into viral transport was the preferred specimen however if a nasopharyngeal aspirate (NPA) had already been performed, this sample was used rather than repeating the diagnostic test. 84.9% of samples collected were nasal swabs with the remainder NPA. This information has been added in the Methods section of the revised manuscript (p.9).

How much was added with the use of viral culture? I am not sure if there is room for this information to be included, but it would be interesting to know if testing by culture added to the virus detections. It is also worth noting that the number of hMPV positives seems very low relative to the other viruses – which causes one to question the sensitivity of the multiplex PCR and immunofluorescent assay for detection of hMPV. Please comment in the manuscript on this.

Response

Of 1630 patients with viruses detected, 34 patients (2.1%) had a virus detected only through culture. We have not included this information in the manuscript as it is not central to the main aims of this study.

We acknowledge that the proportion of children testing positive for hMPV in this cohort were lower than that in other studies and have included it as a point of Discussion (p.16) in the revised manuscript.

Line 55-56 on page 11 to top of page 12: Would note that children with co-detection of viruses were significantly younger compared with children with single virus detection; and while it is true that the percentage in out-of-home care was highest in the co-detection group, it was not statistically higher (as the confidence intervals overlap).

Response

We have amended the manuscript clarify these points in the Results (p.13).

1
2
3
4 *Was there any information available regarding use of antivirals for treatment of influenza? It would*
5 *be informative to include this information in the results, if available, and if there is sufficient space.*

6 **Response**

7 Although data on antiviral use were collected from the follow-up questionnaire, we were unable to
8 assess the role of antivirals in this study as only 9 patients were prescribed them (data not shown).
9

10
11 *Because this was a study which required ILI for enrollment, all patients had fever as part of the case*
12 *definition. This is well noted in the Discussion as a limitation, but would also recommend clarification*
13 *in the Conclusions of the Abstract and throughout the Discussion that "Overall, coinfection has*
14 *limited impact on clinical severity among young children with ILI." This should be clearer, for*
15 *example, in the first and last paragraphs of the Discussion.*

16 **Response**

17 We acknowledge that this is a valid point and have amended the abstract (p.6) and Discussion
18 section (p.14, 16) in the revised manuscript to explicitly state this.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Title

Viral etiology and the impact of co-detection in young children presenting with influenza-like illness

Authors

*Faye J Lim^a, *Zoe V Wake^{b,h}, Avram Levy^{c,d}, Simone Tempone^c, Hannah C Moore^a, Peter C Richmond^{a,b,e}, Nicholas de Klerk^a, Nicholas T Conway^a, Anthony D Keil^f, Paul V Effler^g, David W Smith^{c,d}, Christopher C Blyth^{a, e, f, h} on behalf of the WAIVE group

*joint first authorship

Authors' affiliations

^a Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, PO Box 855, West Perth, Western Australia 6872, Australia

^b Department of General Paediatrics, Princess Margaret Hospital for Children, GPO Box D184, Perth, Western Australia 6840, Australia

^c PathWest Laboratory Medicine WA, QEII Medical Centre, Locked Bag 2009, Nedlands, Western Australia 6909, Australia

^d School of Pathology and Laboratory Medicine, M504, The University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia

^e School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia 6840, Australia

^f Department of Microbiology, PathWest Laboratory Medicine WA, Princess Margaret Hospital for Children, GPO Box D184, Perth, Western Australia 6840, Australia

^g Communicable Disease Control Directorate, Department of Health, Grace Vaughan House, 227 Stubbs Terrace, Shenton Park, Western Australia 6008, Australia

^h Department of Infectious Diseases, Princess Margaret Hospital for Children, GPO Box D184, Perth, Western Australia 6840, Australia

Present address

Nicholas T Conway^{1,2}

¹ Child Health, School of Medicine, University of Dundee, Dundee DD1 9SY, Scotland, UK.

² Tayside Children's Hospital, Ninewells Hospital, NHS Tayside, Dundee DD1 9SY, Scotland, UK.

Keywords

Respiratory infection, Viral infection, Co-detection, Child

Running title

Viral etiology and impact of co-detection

Corresponding author

Faye Janice Lim

Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute

PO Box 855, West Perth, Western Australia, 6872 Australia

Email: Janice.Lim@telethonkids.org.au

Phone: +61 8 9489 7769

Alternate author

A/Professor Christopher C Blyth

School of Paediatrics and Child Health, University of Western Australia

GPO Box D184, Perth, Western Australia 6840, Australia

Email: christopher.blyth@uwa.edu.au

Phone: +61 8 9340 8606

Key points

- Children frequently had multiple respiratory viruses detected
- Although common, children with multiple viruses more frequently had cough and rhinorrhoea
- Children with influenza and respiratory syncytial virus were most frequently hospitalised
- Routine screening and cohorting recommended only for common respiratory pathogens

Author contributions

CCB, PCR, PVE and DWS conducted the WAIVE study. PCR, DWS and CCB conceptualised this study. AL and ST conducted the laboratory work. ZVW and NTC conducted the preliminary data cleaning and analyses. FJL conducted data cleaning and analyses with assistance from HCM, NdK and CCB. FJL and ZVW jointly wrote the first draft of the manuscript. All authors have critically revised and approved of the final version of this manuscript.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word counts

Abstract – 248 words

Manuscript – Approx. 3000 words

For Review Only

Abstract

Background

Children with acute respiratory tract infection (ARTI) frequently exhibit viral-viral co-detection, yet its clinical significance remains contentious. Using data from a prospective cohort of children with influenza-like illness, we described the virology of ARTI and determined the clinical impact of viral-viral co-detection.

Methods

Children aged 6-59 months presenting to a tertiary paediatric hospital with fever and acute respiratory symptoms were enrolled and nasal samples collected during influenza seasons in 2008-2012. Respiratory viruses were identified by culture and PCR. We compared demographics, presenting symptoms and clinical outcomes of children with single viral infection and viral-viral co-detection. We used logistic regression models and estimated marginal means to calculate the adjusted odds ratio and probabilities of symptom presentation, antibiotic prescription or hospitalisation.

Results

1630 of 2356 children (69.2%) had a virus detected, among whom rhinovirus (40.8%), influenza (29.5%) and respiratory syncytial virus (RSV; 26.4%) were most commonly detected. 24% of these had two or more viruses detected. After adjusting for demographic factors, children with co-detection had greater odds of presenting with cough (aOR=1.9, 95% CI:1.2-3.1), rhinorrhoea (aOR=1.8, 95% CI:1.1-2.9) than those with single infection, although both symptoms were common. Children with influenza and RSV combined had the highest probability of hospitalisation

1
2
3 (probability=55%, 95%CI:35-73%), significantly greater than those with influenza
4
5 infection alone (probability=22%, 95%CI:16-29%).
6
7
8

9 **Conclusions**

10 Overall, co-detection has limited impact on clinical severity among children with
11
12 influenza-like illness. However, specific pathogen pairs may be associated with more
13
14 severe outcomes. Routine diagnostics to identify viral co-detection should be
15
16 restricted to common pathogens.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Introduction

Acute respiratory tract infections (ARTI) in children place a significant burden on families and the community. Commonly recognized respiratory viral pathogens include influenza viruses, respiratory syncytial viruses (RSV), parainfluenza viruses, human rhinoviruses, adenoviruses and coronaviruses [1,2]. Advances in laboratory diagnostic techniques have resulted in the discovery of new viruses, including human metapneumovirus (hMPV) and polyomaviruses [3,4], yet a number of these pathogens have uncertain pathogenicity [5,6].

Co-detection can be defined as detection of two or more pathogens in a single sample. With the improved sensitivity, availability and affordability of modern diagnostics, viral-viral co-detections are being increasingly identified. The incidence of viral-viral co-detection has been reported between 15-45%, depending on age, location and testing methods [7-9]. The clinical significance of co-detection in ARTI remains contentious with the literature ranging from negligible to deleterious effects [9,10].

This study describes the virology of ARTI in children aged six months to four years who presented with influenza-like illness during influenza season to a tertiary paediatric hospital in Australia. This study also enabled us to specifically examine the impact of viral-viral co-detection on clinical symptoms and outcomes.

2 Materials and Methods

2.1 Study setting and patients

Western Australia (WA) spans 2.5 million square kilometres with a population of approximately 2.5 million people, 7% of whom are under 5 years of age [11].

Princess Margaret Hospital for Children (PMH) is the only tertiary paediatric hospital in the state and is located in metropolitan Perth where approximately 80% of the population resides [12].

Commencing in 2008, the Western Australia Influenza Vaccine Effectiveness (WAIVE) Study was an observational cohort study established to determine the effectiveness of inactivated influenza vaccine. Patient recruitment was conducted at PMH (and at selected general practises in metropolitan WA in 2008-2009). Due to small numbers recruited and differences in presentation, data from children presenting to general practises were removed from these analyses.

Patient recruitment coincided with the annual influenza seasons. The start and end of influenza seasons were defined by the Infectious Diseases Surveillance Unit at PathWest Laboratory Medicine WA using a combination of indicators, including weekly proportion of laboratory influenza tests positive. As a guide, two consecutive weeks with over 10% influenza test positive often coincides with the beginning of influenza season in WA. Further details on study design are described elsewhere [13].

All children 6-59 months of age presenting to PMH with a history of fever (by parental report) or with a measured temperature of greater than 37.5°C at

1
2
3 presentation, accompanied by at least one acute respiratory symptoms within the
4
5 previous 96 hours, were eligible for enrolment. All children transited through PMH
6
7 emergency department. A portion of these children were subsequently admitted to
8
9 hospital with the remainder discharged home from the emergency department.
10
11 Children with a known immunodeficiency disorder, current or recent
12
13 immunosuppressive treatment, or who received immunoglobulin in the previous
14
15 three months were excluded from the study.
16
17
18
19

20
21 Patient demographics, medical history and presenting symptoms were collected by
22
23 parental questionnaire. Comorbidities recorded included prematurity, asthma,
24
25 chronic cardiac, neurological or respiratory conditions. Influenza vaccination status
26
27 was obtained by parental report and confirmed through the Australian Childhood
28
29 Immunisation Register or by contacting immunisation providers. Vaccination status
30
31 for other vaccines were not collected. A follow-up questionnaire of illness outcomes,
32
33 including details of hospital admission(s), use of antibiotics and time to recovery, was
34
35 provided to families to complete within 7-10 days after enrolment. A retrospective
36
37 review of medical records was undertaken when hospitalisation data were incorrectly
38
39 recorded or missing. No follow-up was conducted for antibiotics use if data were
40
41 missing.
42
43
44
45

46 47 **2.2 Respiratory virus detection**

48
49 Children had bilateral mid-turbinate nasal swabs collected at enrolment (Copan
50
51 Diagnostics Inc., Murrieta, CA). If a nasopharyngeal aspirate had already been
52
53 collected by hospital staff as part of clinical care, this sample was used in lieu of a
54
55 nasal swab. Viral culture (Madin-Darby Canine Kidney cells, Diploid lung fibroblasts)
56
57
58
59
60

1
2
3 and multiplex tandem PCR was used to detect all viruses except picornaviruses and
4
5 hMPV [14,15]. Picornaviruses were detected using nested PCR [16] targeting the
6
7 5'UTR of the picornavirus genome with sequencing used to assist with identification
8
9 of rhinoviruses and enteroviruses. hMPV was tested using an immunofluorescent
10
11 assay (Simulfluor hMPV Immunofluorescent Assay; Millipore, Temecula, CA) and
12
13 PCR. All patients were subjected to the same panel of tests and testing methods
14
15 were consistent throughout the study period with the exception of testing for hMPV;
16
17 testing for hMPV was based on clinical need. While both immunofluorescence and
18
19 PCR assays were used throughout the study period, PCR testing was more common
20
21 in later years.
22
23
24
25
26

27 For all viruses (except hMPV), positive viral detection was defined as detection by
28
29 viral culture and/or PCR. Positive detection of hMPV was defined as detection by
30
31 immunofluorescence and/or PCR. All influenza types/subtypes (i.e. influenza
32
33 A/H1N1, A/H3N2 and B) were grouped for analysis. Similarly, subgroups of
34
35 parainfluenza viruses (i.e. parainfluenza types 1-4) were grouped together for
36
37 analysis. Infection was defined as detection of one or more of rhinovirus, influenza,
38
39 RSV, parainfluenza, adenovirus, coronavirus or hMPV. Co-detection was defined as
40
41 detection of two or more viruses in a single diagnostic sample.
42
43
44
45
46

47 **2.3 Definitions and statistical analysis**

48 Prematurity was defined as less than 37 weeks of gestation at birth. Out-of-home
49
50 care was defined as attendance at playgroup, mothers' group, day-care centre,
51
52 kindergarten or preschool. Length of stay in hospital refers to the duration from
53
54 admission to discharge date. Symptoms investigated included cough, rhinorrhoea,
55
56
57
58
59
60

1
2
3 wheeze, dyspnoea, rash, diarrhoea and vomiting while outcomes investigated were
4
5 antibiotic prescription and hospital admission.
6
7

8
9
10 Data cleaning and analyses were performed in Microsoft Excel, EpiBasic [17] and
11
12 SPSS version 23 (SPSS Inc., Chicago, IL). Categorical variables were compared
13
14 using Pearson's chi-squared tests. Logistic regression models were used to
15
16 calculate odds ratios (OR) with 95% confidence intervals (CI) to compare those with
17
18 single infection to those with co-detection. Dependent variables were symptom (e.g.
19
20 presence of cough or rhinorrhoea) and outcome variables (e.g. hospitalisation or use
21
22 of antibiotics).
23
24

25
26
27 We calculated adjusted ORs (aORs) by including the following covariates in the
28
29 logistic regression models: age, gender, Aboriginal status, prematurity, presence of
30
31 comorbidities, out-of-home care and household smoking. Age was included as a
32
33 categorical variable in the models and were divided into 6-11 months, 12-23 months,
34
35 2 years, 3 years and 4 years (reference group). Covariates were selected based on
36
37 known epidemiological or clinical risk factors for co-detection. Data from all patients
38
39 were included in the adjusted models unless they had missing data on one or more
40
41 covariates. To investigate the impact of specific pathogen pairs, analyses were
42
43 repeated for the most common pathogen pairs. Estimated marginal means of logistic
44
45 regression models were used to calculate probabilities with 95% CIs for antibiotic
46
47 prescribing and hospitalisation for common pathogen pairs.
48
49
50
51
52
53
54
55
56
57
58
59
60

2.4 Ethical approvals

This study was approved by the PMH Human Research Ethics Committee (1673/EP), the Western Australian Aboriginal Health Ethics Committee (212 06/08) and the University of Western Australia Research Ethics Committee (RA/4/1/6456).

3 Results

Of 2715 patients recruited from 2008 to 2012, data for 2356 patients were available for analysis. Reasons for exclusion included incorrect or unknown age (n=154, 42.9% of all excluded patients), recruitment from general practice in 2008-2009 (n=131, 36.5%), incomplete pathogen testing (n=29, 8.1%), unknown vaccination history (n=7, 1.9%), incomplete data (n=12, 3.3%), multiple enrolments for the same episode of illness (n=3, 0.8%), withdrawal from the study (n=23, 6.4%).

Of the 2356 patients enrolled, the majority (n=1848, 78.4%) were enrolled while presenting to PMH emergency department. Of these 6.3% (n=117) were subsequently admitted to hospital. The median age was 22.0 months (interquartile range=14.0-35.0), 54.9% were male and 5.7% were of Aboriginal or Torres Strait Islander decent. Children born preterm accounted for 13.5% (n=319) of patients. Children with comorbidities accounted for 15.1% (n=355) of this cohort. Of those that had one or more comorbidity, asthma (n=218, 61.4%) and other chronic respiratory conditions (n=54, 15.2%) were most common.

Of 2356 patients, 52.8% (n=1244) completed questions relating to outcomes (e.g. antibiotics use). Although parents were requested to complete these questions 7-10 days post-enrolment, yet the mean time to completion was 19.3 days and ranged

1
2
3 from 0 to 149 days (median=10 days). Data on antibiotic prescription post-enrolment
4
5 were available for 51.0% (n=1201) of patients, of whom 483 (40.2%) were
6
7 prescribed antibiotics. Combining data from questionnaires and review of hospital
8
9 records resulted in near-complete data on hospitalisation (99.4%, n=2341), of whom
10
11 610 (26.1%) were hospitalized. Of those who were admitted to hospital, the median
12
13 length of stay was 2 days (interquartile range=1-3).
14
15

16
17
18 Overall, 1630 patients (69.2%) tested positive for a virus. Of those with at least one
19
20 virus detected, the most common were rhinovirus (n=665, 40.8%), influenza (n=481,
21
22 29.5%) and RSV (n=431, 26.4%; Figure 1). Of those with a virus detected, 24.8%
23
24 (n=404) had at least one other virus co-detected. Of these, 350 (86.6%) had 2
25
26 viruses detected, 52 (12.9%) had 3 viruses detected and the remainder with 4 or
27
28 more viruses.
29
30

31
32
33 A greater proportion of children with multiple viruses detected were less than 2 years
34
35 old (65.4%) compared to those with a single virus infection (51.2%, $p < 0.001$; Table
36
37 1). Those with co-detection also had greater odds of presenting with cough and
38
39 rhinorrhoea compared to those with single infection, although both symptoms were
40
41 common in both groups (Table 2). This effect remained after adjusting for other
42
43 covariates. Of note, although less common, diarrhoea was more frequently observed
44
45 in children with viral co-detection. There were no significant differences in the odds
46
47 of being prescribed antibiotics (aOR=1.1, 95%CI: 0.8,1.5) or hospitalised (aOR=1.1,
48
49 95%CI: 0.8,1.4) between patients with single infection and co-detection (Table 2).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We then selected the three most common pathogens (rhinovirus, influenza and RSV)
4 and investigated associations of specific pathogen pairs with antibiotic prescription
5 and hospitalisation. After adjusting for other covariates, patients with both influenza
6 and RSV detected had a 52% probability (95% CI:28%-76%) of being prescribed
7 antibiotics with a trend towards more frequent prescription when compared with
8 those with influenza or RSV infection alone (Figure 2). Similarly, the probability of
9 being hospitalised was highest in those with influenza and RSV detected
10 (probability=55%, 95% CI:35-73%); significantly greater when compared with those
11 with influenza infection alone (probability=22%, 95%CI:16-29%; Figure 3) and with a
12 trend observed compared with RSV infection alone (probability=43%, 95%CI:36-
13 51%).
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **4 Discussion**

31
32 This is one of the largest, single-site prospective studies of children up to 4 years of
33 age that specifically investigates the incidence of and clinical outcomes associated
34 with viral-viral co-detection. Our findings demonstrate that although differences in
35 demographics, risk factors and symptoms are identifiable, in general, viral-viral co-
36 detection is unlikely to be associated with more severe clinical illness among young
37 children with influenza-like illness. Specific pathogen pairs may be associated with
38 an increased probability of hospitalisation as was observed with influenza and RSV.
39
40 This finding has implications in paediatric healthcare facilities where isolation of all
41 children with acute respiratory viral infection is difficult during periods of peak
42 respiratory virus activity and cohorting of children is frequently required prior to the
43 availability of diagnostic test results.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We detected small differences in the symptoms presented by patients with single
4 infection compared to those with co-detection. However, these symptoms were
5 common and therefore, likely to be of little clinical relevance. On the other hand, the
6 clinical outcomes chosen (i.e. antibiotics use and hospitalisation) were more
7 indicative of disease severity but may be subject to clinical judgement and therefore,
8 be less sensitive measures of disease severity. Accordingly, we observed no
9 significant differences in the outcomes for children with single infection and those
10 with co-detection.
11
12
13
14
15
16
17
18
19

20
21
22 This is consistent with data from previous systematic reviews, which found negligible
23 differences between outcomes in children and adults with co-detection compared to
24 peers with single infection [18,19]. However, further analyses by pathogen pairs
25 suggest that some combinations of specific viral pathogens, such as influenza and
26 RSV, are potentially more significant than others. This corroborates data from our
27 recently completed systematic review that specifically investigated clinical outcomes
28 in children with co-detection and found no differences overall but suggest that some
29 pathogen specific effects may be present [20]. Our data suggest that future research
30 in this area should segregate analysis by specific pathogen pairs where numbers
31 allow.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 We chose to exclude bocavirus and enterovirus detections from the analyses as their
48 pathogenicity in ARTI is still not well-established. Bocavirus is often implicated in
49 both symptomatic and asymptomatic co-detection and is thought to have a
50 prolonged period of shedding [6]; both features which may confound any
51 associations between co-detection and clinical severity. On the other hand, studies
52
53
54
55
56
57
58
59
60

1
2
3 on the role of enteroviruses in ARTI are suggestive of pathogenicity [21], however
4
5 the numbers are small. For these reasons, detections of both viruses were excluded
6
7 from the analyses presented here. Repeat analyses including these viruses did not
8
9 change the overall findings (see Supplementary Tables 1 and 2).
10
11

12
13
14 An important consideration when interpreting these findings is the inability to
15
16 distinguish between active (and pathogenic) infection and viral shedding. Prolonged
17
18 viral shedding for some respiratory viruses, particularly rhinovirus, have been well-
19
20 documented [22,23]. Quantitative analyses may be of assistance in distinguishing
21
22 these clinical states yet has not become commonplace in the diagnostic laboratory
23
24 for respiratory viruses.
25
26

27
28
29 One limitation of our study is that only children presenting to one hospital with
30
31 influenza-like illness and fever were eligible for enrolment in this study.
32
33

34 Consequently, it is possible that these children were at the more severe end of the
35
36 disease spectrum which may bias our results. During the course of this study, there
37
38 was a shift from using an antigen-based assay to using PCR when detecting hMPV,
39
40 although both methods were used throughout the study period. We have elected to
41
42 include detections from both methods but acknowledge that differences in the
43
44 performance of these methods would mean that potential cases of hMPV may have
45
46 been missed in earlier samples. These changes, as well as clinical discretion in
47
48 testing for hMPV, may explain the lower proportions of hMPV detections in this
49
50 cohort compared to other studies [24,25].
51
52
53
54
55
56
57
58
59
60

1
2
3 Further limitations of this study include missing outcomes data, particularly for
4 antibiotic prescription. In addition, data on diagnosis at discharge were not collected,
5 which may have helped to indicate the severity of symptoms. Moreover, despite
6 enrolling nearly 2500 children, the number of patients with infections with specific
7 pathogens and pathogen-pairs were relatively small.
8
9

10
11
12
13
14
15
16 Future studies using routinely collected, linked administrative data may assist in
17 addressing both issues. Nonetheless, this is one of the largest single-site studies
18 specifically investigating the effects of co-detection in young children using a wide
19 panel of respiratory pathogens. Our results are similar to those reported elsewhere,
20 adding to the validity of the findings [26].
21
22
23
24
25
26
27
28

29 We conclude that the impact of co-detection on disease severity in children
30 presenting with influenza-like illness is likely to be limited to specific pathogen pairs.
31 Therefore, routine screening for co-detection in this population should be restricted
32 to common respiratory pathogens and efforts to reduce cross infection should focus
33 on these specific pathogens.
34
35
36
37
38
39
40
41
42

43 **5 Funding**

44
45 This work was supported by the Western Australia Department of Health; The
46 University of Western Australia [University Postgraduate Award to FJL]; the National
47 Health and Medical Research Council [APP1045668 to HCM and FJL, APP1034254
48 to HCM, APP1111596 to CCB] and the Western Australian Department of
49 Health/Raine Medical Research Foundation Clinician Research Fellowship to CCB.
50
51
52
53
54
55
56 No external funding was provided for other authors.
57
58
59
60

6 Conflicts of interest

None to declare.

7 Acknowledgements

We would like to acknowledge Peter Jacoby for his assistance with the logistic regression analyses and Gabriela Willis for her assistance with cross-checking the data. We would like to thank members of the Vaccine Trials Group, particularly Christine Robins, who managed the study. We would also like to thank all the parents and children who have participated in the WAIVE study.

8 References

1. Mahony JB. Detection of respiratory viruses by molecular methods. *Clin Microbiol Rev.* **2008**;21(4):716–47.
2. Monto AS. Epidemiology of viral respiratory infections. *Am J Med.* **2002**;112(Supplement 6A):4S – 12S.
3. Debiaggi M, Canducci F, Ceresola ER, Clementi M. The role of infections and coinfections with newly identified and emerging respiratory viruses in children. *Viol J.* **2012**;9.
4. Bialasiewicz S, Whiley DM, Lambert SB, Jacob K, Bletchly C, Wang D, et al. Presence of the newly discovered human polyomaviruses KI and WU in Australian patients with acute respiratory tract infection. *J Clin Virol.* **2008**;41(2):63–8.
5. Linder JE, Kraft DC, Mohamed Y, Lu Z, Heil L, Tollefson S, et al. Human

- 1
2
3 rhinovirus C: Age, season, and lower respiratory illness over the past 3
4
5 decades. *J Allergy Clin Immunol*. **2013**;131(1):69–77.e6.
6
7
8 6. Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Söderlund-
9
10 Venermo M. Human bocavirus—the first 5 years. *Rev Med Virol*.
11
12 **2012**;22(1):46–64.
13
14
15 7. Aberle JH, Aberle SW, Pracher E, Hutter H-P, Kundi M, Popow-Kraupp
16
17 T. Single versus dual respiratory virus infections in hospitalized infants:
18
19 impact on clinical course of disease and interferon-[gamma] response.
20
21 *Pediatr Infect Dis J*. **2005**;24(7):605–10.
22
23
24
25 8. Peng D, Zhao D, Liu J, Wang X, Yang K, Xicheng H, et al.
26
27 Multipathogen infections in hospitalized children with acute respiratory
28
29 infections. *Virol J*. **2009**;6(155):155.
30
31
32 9. Kouni S, Karakitsos P, Chranioti A, Theodoridou M, Chrousos G, Michos
33
34 A. Evaluation of viral co-infections in hospitalized and non-hospitalized
35
36 children with respiratory infections using microarrays. *Clin Microbiol*
37
38 *Infect*. **2013**;19(8):772–7.
39
40
41
42 10. Martin ET, Kuypers J, Wald A, Englund JA. Multiple versus single virus
43
44 respiratory infections: viral load and clinical disease severity in
45
46 hospitalized children. *Influenza Other Respi Viruses*. **2012**;6(1):71–7.
47
48
49 11. Codde J. Rates Calculator. 9.5.5 ed. Perth, Western Australia: Health
50
51 Information Centre, Department of Health; **2013**.
52
53
54 12. Australian Bureau of Statistics. Regional Population Growth, Australia,
55
56 2012-13 [Internet]. Canberra; **2015** [cited 2015 Nov 13]. Available from:
57
58
59
60

1
2
3 http://www.abs.gov.au/ausstats/abs@.nsf/Previousproducts/3218.0Feat
4 ure Article22012-
5
6
7
8 13?opendocument&tabname=Summary&prodno=3218.0&issue=2012-
9
10 13&num=&view=
11

- 12
13 13. Blyth CC, Jacoby P, Effler P V, Kelly H, Smith DW, Robins C, et al.
14 Effectiveness of trivalent flu vaccine in healthy young children.
15 *Pediatrics*. **2014**;133(5):e1218–25.
16
17
18
19 14. Chidlow GR, Harnett G, Williams S, Levy A, Speers D, Smith DW.
20 Duplex real-time reverse transcriptase PCR assays for rapid detection
21 and identification of pandemic (H1N1) 2009 and seasonal influenza
22 A/H1, A/H3, and B viruses. *J Clin Microbiol*. **2010**;48(3):862–6.
23
24
25
26
27
28
29 15. Chidlow GR, Harnett GB, Shellam GR, Smith DW. An economical
30 tandem multiplex real-time PCR technique for the detection of a
31 comprehensive range of respiratory pathogens. *Viruses*. **2009**;1(1):42–
32 56.
33
34
35
36
37
38
39 16. Ireland DC, Kent J, Nicholson KG. Improved detection of rhinoviruses in
40 nasal and throat swabs by seminested RT-PCR. *J Med Virol*.
41
42
43
44 **1993**;40(2):96–101.
45
46
47 17. Juul S, Frydenberg M. *EpiBasic*. 2.0 ed. **2011**.
48
49 18. Asner SA, Science ME, Tran D, Smieja M, Merglen A, Mertz D. Clinical
50 disease severity of respiratory viral co-infection versus single viral
51 infection: A systematic review and meta-analysis. *PLoS One*.
52
53
54
55
56 **2014**;9(6):e99392.
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Goka EA, Vallely PJ, Mutton KJ, Klapper PE. Single and multiple respiratory virus infections and severity of respiratory disease: a systematic review. *Paediatr Respir Rev.* **2014**;15(4):363–70.
 20. Lim FJ, de Klerk N, Blyth CC, Fathima P, Moore HC. Systematic review and meta-analysis of respiratory viral coinfections in children. *Respirology.* **2016**;21(4):648–55.
 21. Imamura T, Oshitani H. Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. *Rev Med Virol.* **2015**;25(2):102–14.
 22. Loeffelholz MJ, Trujillo R, Pyles RB, Miller AL, Alvarez-Fernandez P, Pong DL, et al. Duration of rhinovirus shedding in the upper respiratory tract in the first year of life. *Pediatrics.* **2014**;134(6):1144–50.
 23. Jartti T, Lehtinen P, Vuorinen T, Koskenvuo M, Ruuskanen O. Persistence of rhinovirus and enterovirus RNA after acute respiratory illness in children. *J Med Virol.* **2004**;72(4):695–9.
 24. Fathima S, Lee B, May-Hadford J, Mukhi S, Drews S. Use of an Innovative Web-Based Laboratory Surveillance Platform to Analyze Mixed Infections Between Human Metapneumovirus (hMPV) and Other Respiratory Viruses Circulating in Alberta (AB), Canada (2009–2012). *Viruses. Molecular Diversity Preservation International;* **2012**;4(11):2754–65.
 25. Ali SA, Williams J V, Chen Q, Faori S, Shehabi A, Al Jundi E, et al. Human metapneumovirus in hospitalized children in Amman, Jordan. *J*

1
2
3 Med Virol. **2010**;82(6):1012–6.
4

- 5 26. Dierig A, Heron LG, Lambert SB, Yin JK, Leask J, Chow MYK, et al.
6
7 Epidemiology of respiratory viral infections in children enrolled in a study
8 of influenza vaccine effectiveness. Influenza Other Respi Viruses.
9
10 **2014**;8(3):293–301.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Review Only

1
2
3
4 **9 Tables**5
6 **9.1 Table 1 – Cohort characteristics by infection status**
7
8
9

Description	Frequency (n=2356)								
	No pathogen (n=726)			Single infection (n=1226)			Co-detection (n=404)		
	n	%	(95% CI)	n	%	(95% CI)	n	%	(95% CI)
Aged less than 2 years	382	52.62	(48.91-56.30)	628	51.22	(48.38-54.06)	264	65.35	(60.48-69.98)
Male	397	54.68	(50.98-58.35)	668	54.49	(51.65-57.30)	228	56.44	(51.44-61.33)
Aboriginal or Torres Strait Islander descent	33	4.55	(3.15-6.32)	71	5.79	(4.55-7.25)	31	7.67	(5.27-10.71)
Born preterm	102	14.05	(11.60-16.79)	158	12.89	(11.06-14.89)	59	14.60	(11.31-18.43)
One or more comorbidities	117	16.12	(13.51-19.00)	183	14.93	(12.98-17.05)	55	13.61	(10.42-17.35)
More than 4 hours in out-of-home care	442	60.88	(57.22-64.45)	825	67.29	(64.59-69.91)	299	74.01	(69.44-78.22)
Smoking in household	154	21.21	(18.29-24.37)	283	23.08	(20.75-25.55)	107	26.49	(22.24-31.07)
Influenza vaccine on year of admission	188	25.90	(22.74-29.24)	303	24.71	(22.32-27.23)	100	24.75	(20.62-29.26)

37
38
39
40
41
42
43
44
45
46
47
48
49

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

5 Note: CI=Confidence Intervals. Exact 95% CI presented. Denominators include cases with missing data. Detections of enterovirus
6 or bocavirus were ignored in counts of single and co-detection.

For Review Only

1
2
3
4 7 **9.2 Table 2 – Frequency and logistic regression models of symptoms and outcomes by infection type**
5
6
7
8

Description	Frequency		Logistic regression models	
	Single infection (n=1226)		Co-detection (n=404)	
	% (95% CI)	% (95% CI)	OR ^a (95% CI)	aOR ^{a,b} (95% CI)
Symptoms				
Cough	88.66 (86.75-90.38)	93.32 (90.43-95.55)	1.95 (1.24-3.06)	1.94 (1.21-3.13)
Rhinorrhoea	88.09 (86.15-89.85)	93.32 (90.43-95.55)	2.07 (1.32-3.23)	1.79 (1.12-2.85)
Wheezing	43.56 (40.76-46.39)	49.01 (44.03-54.00)	1.26 (1.01-1.58)	1.20 (0.94-1.52)
Dyspnoea	45.84 (43.02-48.68)	50.74 (45.75-55.72)	1.23 (0.98-1.55)	1.15 (0.91-1.47)
Rash	17.86 (15.76-20.12)	14.11 (10.86-17.89)	0.75 (0.55-1.03)	0.69 (0.49-0.95)
Diarrhoea	20.39 (18.17-22.76)	27.23 (22.94-31.85)	1.47 (1.13-1.90)	1.33 (1.01-1.74)
Vomiting	38.58 (35.85-41.37)	42.82 (37.94-47.81)	1.19 (0.94-1.50)	1.16 (0.91-1.48)
Outcomes				
Antibiotics given ^c	19.98 (17.78-22.33)	21.53 (17.62-25.87)	1.19 (0.86-1.63)	1.11 (0.79-1.54)
Admitted to hospital	24.55 (22.16-27.06)	26.24 (22.01-30.82)	1.13 (0.87-1.46)	1.09 (0.83-1.44)

1
2
3
4 10 Note: CI=confidence intervals. Denominators include those with missing data. The number of children with missing data are as
5
6 11 follows: cough (n=4 for single infection; n=3 for co-detection), rhinorrhoea (n=4; n=3), wheezing (n=4; n=4), dyspnoea (n=5; n=4),
7
8 12 rash (n=30; n=9), diarrhoea (n=30; n=10), vomiting (n=32; n=9), antibiotics given (n=587; n=199), admitted to hospital (n=6; n=2).
9
10 13 Infections with either enterovirus or bocavirus were ignored in counts of single infection and co-detection.
11
12
13
14

15 15 ^a Models presented are the odds of having a symptom/outcome in children with co-detection compared with children with single
16
17 16 infection.
18

19 17 ^b Models were adjusted for age, gender, Aboriginal status, preterm birth, presence of comorbidities, out-of-home care and
20
21 18 household smoking. All covariates listed were inputted as categorical variables.
22

23
24 19 ^c Data were only available for 639 children with single infection and 205 children with co-detection.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1
2
3 **20 10 Figure legends**
4

5 21 Figure 1 – Frequency of pathogen detection and co-detection
6

7 22 Figure 2 – Probability of post-enrolment antibiotics use by pathogen pairs with 95%
8

9 confidence intervals
10


11 24 Figure 3 - Probability of hospitalisation by pathogen pairs with 95% confidence intervals
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

25 **11 Figures**

26 **11.1 Figure 1 – Frequency of pathogen detection and co-detection**




27

28 Note: RSV=respiratory syncytial virus, hMPV = human metapneumovirus. Detections of enterovirus and bocavirus were excluded

29 from subsequent analyses.


30 **11.2 Figure 2 – Probability of post-enrolment antibiotics use by pathogen pairs with 95% confidence intervals**



31
32 Note: RSV=respiratory syncytial virus.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

33 **11.3 Figure 3 – Probability of hospitalisation by pathogen pairs with 95% confidence intervals**



34
35 Note: RSV=respiratory syncytial virus.

Supplementary Table 1 – Cohort characteristics by infection status (all viruses included)

Description	Frequency (n=2356)								
	No pathogen (n=542)			Single infection (n=1228)			Co-detection (n=586)		
	n	%	(95% CI)	n	%	(95% CI)	n	%	(95% CI)
Aged less than 2 years	279	51.48	(47.18-55.76)	611	49.76	(46.91-52.59)	384	65.53	(61.52-69.38)
Male	293	54.06	(49.76-58.31)	664	54.07	(51.24-56.89)	336	57.34	(53.22-61.38)
Aboriginal or Torres Strait Islander descent	26	4.80	(3.16-6.95)	72	5.86	(4.62-7.33)	37	6.31	(4.48-8.60)
Born preterm	70	12.92	(10.21-16.03)	163	13.27	(11.42-15.30)	86	14.68	(11.91-17.80)
Has 1 or more comorbidities	92	16.97	(13.91-20.40)	186	15.15	(13.19-17.28)	77	13.14	(10.51-16.15)
More than 4 hours in out-of- home care	346	63.84	(59.63-67.89)	812	66.12	(63.40-68.77)	408	69.62	(65.72-73.33)
Has smoking in household	119	21.96	(18.54-25.68)	282	22.96	(20.64-25.42)	143	24.40	(20.98-28.09)
Had influenza vaccine on year of admission	150	27.68	(23.95-31.65)	306	24.92	(22.52-27.44)	135	23.04	(19.69-26.66)

Note: CI=Confidence Intervals. Exact 95% CI presented. Denominators include cases with missing data.

Supplementary Table 2 – Frequency and logistic regression models of symptoms and outcomes by infection type (all viruses)

Description	Frequency		Logistic regression models					
	Single infection (n=1228)		Co-detection (n=586)		Co-detection		Co-detection	
	%	(95% CI)	%	(95% CI)	OR ^a	(95% CI)	aOR ^{a,b}	(95% CI)
Symptoms								
Cough	87.87	(85.91-89.64)	91.47	(88.91-93.60)	1.53	(1.09-2.16)	1.63	(1.12-2.36)
Rhinorrhoea	86.64	(84.61-88.50)	92.32	(89.86-94.34)	1.94	(1.36-2.76)	1.72	(1.18-2.51)
Wheezing	43.08	(40.29-45.90)	48.63	(44.52-52.77)	1.26	(1.03-1.54)	1.23	(0.99-1.53)
Dyspnoea	44.87	(42.06-47.70)	51.19	(47.06-55.31)	1.30	(1.07-1.58)	1.27	(1.03-1.57)
Rash	17.59	(15.50-19.84)	15.70	(12.85-18.90)	0.87	(0.66-1.13)	0.82	(0.62-1.08)
Diarrhoea	19.95	(17.75-22.30)	24.57	(21.14-28.27)	1.31	(1.03-1.65)	1.17	(0.91-1.50)
Vomiting	38.93	(36.19-41.72)	40.44	(36.44-44.54)	1.06	(0.86-1.29)	1.03	(0.84-1.28)
Outcomes								
Antibiotics given ^c	19.71	(17.52-22.04)	20.99	(17.76-24.51)	1.09	(0.82-1.44)	0.98	(0.73-1.31)
Admitted to hospital	24.35	(21.97-26.85)	28.16	(24.55-31.99)	1.22	(0.97-1.52)	1.18	(0.92-1.49)

1
2 Note: CI=confidence intervals. Denominators include those with missing data. The number of children with missing data are as follows: cough
3
4 (n=4 for single infection; n=3 for co-detection), rhinorrhoea (n=4; n=3), wheezing (n=4; n=4), dyspnoea (n=5; n=4), rash (n=32; n=13), diarrhoea
5
6 (n=33; n=14), vomiting (n=34; n=13), antibiotics given (n=601; n=283), admitted to hospital (n=6; n=2).
7
8

9
10
11 ^a Models presented are the odds of having a symptom/outcome in children with co-detection compared with children with single infection.

12
13 ^b Models were adjusted for age, gender, Aboriginal status, preterm birth, presence of comorbidities, out-of-home care and household smoking.

14
15 All covariates listed were inputted as categorical variables.

16
17
18 ^c Data were only available for 627 children with single infection and 283 children with co-detection.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Title

Viral etiology and the impact of ~~coinfection~~co-detection in young children presenting with influenza-like illness

Authors

*Faye J Lim^a, *Zoe V Wake^{b,h}, Avram Levy^{c,d}, Simone Tempone^c, Hannah C Moore^a, Peter C Richmond^{a,b,e}, Nicholas de Klerk^a, Nicholas T Conway^a, Anthony D Keil^f, Paul V Effler^g, David W Smith^{c,d}, Christopher C Blyth^{a,g,e,f,h} on behalf of the WAIVE group

*joint first authorship

Authors' affiliations

^a Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, PO Box 855, West Perth, Western Australia 6872, Australia

^b Department of General Paediatrics, Princess Margaret Hospital for Children, GPO Box D184, Perth, Western Australia 6840, Australia

^c PathWest Laboratory Medicine WA, QEII Medical Centre, Locked Bag 2009, Nedlands, Western Australia 6909, Australia

^d School of Pathology and Laboratory Medicine, M504, The University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia

^e School of Paediatrics and Child Health, The University of Western Australia, GPO Box D184, Perth, Western Australia 6840, Australia

^f Department of Microbiology, PathWest Laboratory Medicine WA, Princess Margaret Hospital for Children, GPO Box D184, Perth, Western Australia 6840, Australia

^g Communicable Disease Control Directorate, Department of Health, Grace Vaughan House, 227 Stubbs Terrace, Shenton Park, Western Australia 6008, Australia

^h Department of Infectious Diseases, Princess Margaret Hospital for Children, GPO Box D184, Perth, Western Australia 6840, Australia

Present address

Nicholas T Conway^{1,2}

¹ Child Health, School of Medicine, University of Dundee, Dundee DD1 9SY, Scotland, UK.

² Tayside Children's Hospital, Ninewells Hospital, NHS Tayside, Dundee DD1 9SY, Scotland, UK.

Keywords

Respiratory infection, Viral infection, ~~Coinfection~~Co-detection, Child

Running title

Viral etiology and impact of ~~coinfection~~co-detection

Corresponding author

Faye Janice Lim

Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute

PO Box 855, West Perth, Western Australia, 6872 Australia

Email: Janice.Lim@telethonkids.org.au

Phone: +61 8 9489 7769

Alternate author

A/Professor Christopher C Blyth

School of Paediatrics and Child Health, ~~The~~ University of Western Australia

~~7~~GPO Box D184, Perth, Western Australia 6840, Australia

Email: christopher.blyth@uwa.edu.au

Phone: +61 8 9340 8606

Key points

- ~~Coinfection with respiratory virus occurs frequently in c~~Children frequently had multiple respiratory viruses detected
- Although common, children with multiple viruses more frequently had cough and rhinorrhoea ~~were more frequent in coinfecting children~~
- ~~These Children~~ with influenza and ~~+~~respiratory syncytial virus were most frequently tended to be hospitalised
- Routine screening and cohorting recommended only for common respiratory pathogens

Author contributions

CCB, PCR, PVE and DWS conducted the WAIVE study. PCR, DWS and CCB conceptualised ~~thi~~se study. AL and ST conducted the laboratory work. ZVW and NTC conducted the preliminary data cleaning and analyses. FJL conducted data cleaning and analyses with assistance from HCM, NdK and CCB. FJL and ZVW jointly wrote the first draft of the manuscript. All authors have critically revised and approved of the final version of this manuscript.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word counts

Abstract – ~~249~~248 words

Manuscript – Approx. ~~32~~32000 words

For Review Only

Abstract

Background

~~Viral coinfection in children with acute respiratory tract infection (ARTI) is frequently reported to exhibit viral-viral co-detection, yet its clinical significance remains contentious. Using data from a prospective cohort of children with influenza-like illness, we described the virology of ARTI and determined the clinical impact of viral-viral co-detection.~~

Methods

~~Children aged 6-59 months presenting to a tertiary paediatric hospital with fever and acute respiratory symptoms were enrolled and nasal samples collected in an influenza vaccine effectiveness study during influenza seasons in from 2008 to 2012. Respiratory viruses were identified by culture and PCR from nasal swabs. We compared the demographics, presenting symptoms and clinical outcomes of children with single viral infection and viral-viral co-detection. We then used logistic regression models and estimated marginal means to calculate the adjusted odds ratio and probabilities of symptom presentation, antibiotic prescription or hospitalisation, adjusted for demographic factors.~~

Results

~~Of 2487 eligible patients, 1728/1630 of 2356 children (69.2%) had a virus detected, among whom rhinovirus (40.8%), influenza (29.5%) and respiratory syncytial virus (RSV; 26.4%) were most commonly detected. 24% of these had of which 24% were coinfected with two or more viruses detected. After Rhinovirus (40%), influenza (29%) and respiratory syncytial virus (RSV; 27%) were the most commonly detected~~

viruses. ~~a~~ Adjusting for ~~other demographic~~ factors, children with ~~co-detection~~ ~~coinfection~~ had greater odds of presenting with cough (aOR=~~2.01~~.9, 95% CI=~~1.32~~-~~3.12~~), ~~and~~ rhinorrhoea (aOR=1.98, 95% CI=~~1.21~~-2.9) than those with single infection, although both symptoms were common. ~~Children with Comparing virus-virus combinations,~~ influenza and RSV combined ~~was associated with~~ had the the highest ~~st~~ probability of ~~antibiotics prescription (probability=58%, 95%CI=33-79%)~~ and hospitalisation (probability=54%, 95%CI=~~35~~-73%), ~~significantly greater than those with influenza infection alone (probability=22%, 95%CI:16-29%).~~

Conclusions

Overall, ~~coinfection~~ ~~co-detection~~ has limited impact on clinical severity ~~among children with influenza-like illness~~. However, specific pathogen pairs may be associated with more severe outcomes. ~~Routine diagnostics to identify viral~~ Future research should segregate by pathogen where feasible. ~~Routine screening for coinfection~~ ~~co-detection~~ should be restricted to common pathogens.

1 Introduction

Acute respiratory tract infections (ARTI) in children place a significant burden on families and the community. Commonly recognized respiratory viral pathogens include influenza viruses, respiratory syncytial viruses (RSV), parainfluenza viruses, human rhinoviruses, adenoviruses and coronaviruses [1,2]. Advances in laboratory diagnostic techniques have resulted in the discovery of new viruses, including human metapneumovirus (hMPV) and polyomaviruses [3,4]. ~~yet a number of these pathogens have~~ ~~These advances have also enabled greater delineation between pathogenic viruses and viruses of~~ uncertain pathogenicity [5,6].

~~Coinfection~~ ~~Co-detection~~ can be defined as detection of two or more pathogens in a single sample. With the improved sensitivity, availability and affordability of modern diagnostics, viral-viral ~~coinfection~~ ~~co-detection~~s are being increasingly identified. The incidence of viral-viral ~~coinfection~~ ~~co-detection~~ has been reported between 15-45%, depending on age, location and testing methods [7-9]. The clinical significance of ~~coinfection~~ ~~co-detection~~ in ARTI remains contentious ~~with the literature ranging as~~ ~~current evidence ranges~~ from negligible to deleterious effects [9,10].

This study describes the virology of ARTI in children aged six months to four years ~~who~~ ~~presented~~ ~~to a paediatric emergency department~~ with influenza-like illness ~~during influenza season to a tertiary paediatric hospital in Australia. This study also enabled us to specifically examine, and determines~~ the impact of viral-viral ~~coinfection~~ ~~co-detection~~ on clinical symptoms and outcomes.

2 Materials and Methods

2.1 Study setting and patients

Western Australia (WA) spans 2.5 million square kilometres with a population of approximately 2.5 million people, 7% of whom are under 5 years of age [11].

Princess Margaret Hospital for Children (PMH) is the only tertiary paediatric hospital in the state and is located in metropolitan Perth where approximately 80% of the population resides [12].

Commencing in 2008, the Western Australia Influenza Vaccine Effectiveness (WAIVE) Study was an observational cohort study established to determine the effectiveness of inactivated influenza vaccine commenced in 2008. Patient recruitment was conducted at PMH (and at selected general practises in metropolitan WA in 2008-2009). Due to small numbers recruited and differences in presentation, data from children presenting to general practises were removed from these analyses.

Patient recruitment coincided with the annual influenza seasons. and is an observational study conducted during the annual influenza season. The start and end of influenza seasons were defined by the Infectious Diseases Surveillance Unit at PathWest Laboratory Medicine WA using a combination of indicators, including weekly proportion of laboratory influenza tests positive. As a guide, two consecutive weeks with over 10% influenza test positive often coincides with the beginning of influenza season in WA. Further details on The study design are is described elsewhere [13].

1
2
3
4
5
6
7 ~~In summary, A~~all children 6-59 months of age presenting to PMH with a history of
8 fever (by parental report) or with a measured temperature of greater than 37.5°C at
9 presentation, accompanied by at least one acute respiratory symptoms within the
10 previous 96 hours, were eligible for enrolment. All children transited through PMH
11 emergency department. A portion of these children were subsequently admitted to
12 hospital with the remainder discharged home from the emergency department. While
13 the bulk of recruitment occurred at PMH emergency department, children may also
14 be recruited from PMH inpatient facilities or from general practices (2008 only).
15 Influenza seasons each year were determined by influenza surveillance data in the
16 state [13]. Children with a known immunodeficiency disorder, current or recent
17 immunosuppressive treatment, or who received immunoglobulin in the previous
18 three months were excluded from the study.
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Patient demographics, medical history and presenting symptoms were collected by
33 parental questionnaire. Comorbidities recorded included prematurity, asthma,
34 chronic cardiac, neurological or respiratory conditions. Influenza vaccination status
35 was obtained by parental report and confirmed through the Australian Childhood
36 Immunisation Register or by contacting immunisation providers. Vaccination status
37 for other vaccines were not collected. A follow-up questionnaire of illness outcomes,
38 including details of hospital admission(s), use of antibiotics and time to recovery, was
39 provided to families to complete within 7-10 days after enrolment. A retrospective
40 review of medical records was undertaken when hospitalisation data were incorrectly
41 recorded or missing. No follow-up was conducted for antibiotics use if data were
42 missing.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2.2 Respiratory virus detection

Children had ~~a bilateral mid-turbinate nasopharyngeal-nasal swabs or aspirate~~ collected at enrolment (Copan Diagnostics Inc., Murrieta, CA). If a nasopharyngeal aspirate had already been collected by hospital staff as part of clinical care, this sample was used in lieu of a nasal swab. Viral culture (Madin-Darby Canine Kidney cells, Diploid lung fibroblasts) and multiplex tandem PCR was used to detect all viruses except ~~enterovirus, rhinovirus, picornaviruses~~ and hMPV [14,15]. ~~Enteroviruses and rhinoviruses~~ Picornaviruses were detected using nested PCR [16] targeting the 5'UTR of the picornavirus genome with sequencing used to assist with identification of rhinoviruses and enteroviruses ~~speciation~~. hMPV was tested using an immunofluorescent assay (Simulfluor hMPV Immunofluorescent Assay; Millipore, Temecula, CA) and PCR. All patients were subjected to the same panel of tests and testing methods were consistent throughout the study period with the exception of testing for hMPV; testing for hMPV was based on clinical need. While both immunofluorescence and PCR assays were used throughout the study period, PCR testing was more common in later years.

For all viruses (except hMPV), positive viral detection was defined as detection by viral culture and/or PCR. Positive detection of hMPV was defined as detection by immunofluorescence and/or PCR. All influenza types/subtypes (i.e. influenza A/H1N1, A/H3N2 and B) were grouped for analysis. Similarly, sSubgroups of ~~influenza viruses and~~ parainfluenza viruses (i.e. parainfluenza types 1-4) were grouped together for analysis. Infection was defined as detection of one or more of rhinovirus, influenza, RSV, parainfluenza, adenovirus, coronavirus or hMPV.

1
2
3
4
5
6
7 ~~Coinfection~~Co-detection was defined as detection of two or more viruses in a single
8 diagnostic sample.
9

10 11 12 **2.3 Definitions and statistical analysis** 13

14 Prematurity was defined as less than 37 weeks of gestation at birth. Out-of-home
15 care was defined as attendance at playgroup, mothers' group, day-care centre,
16 kindergarten or preschool ~~for four or more hours per week~~. Length of stay in hospital
17 refers to the duration from admission to discharge date. Symptoms investigated
18 included cough, rhinorrhoea, wheeze, dyspnoea, rash, diarrhoea and vomiting while
19 outcomes investigated were antibiotic prescription and hospital admission.
20
21

22
23
24
25
26
27
28 Data cleaning and analyses were performed in Microsoft Excel, EpiBasic [17] and
29 SPSS version 23~~2~~ (SPSS Inc., Chicago, IL). Categorical variables were compared
30 using Pearson's chi-squared tests. Logistic regression models were used to
31 calculate odds ratios (OR) with 95% confidence intervals (CI) to compare those with
32 single infection to those with ~~coinfection~~co-detection. Dependent variables were
33 symptom (e.g. presence of cough or rhinorrhoea) and outcome variables (e.g.
34 hospitalisation or use of antibiotics).
35
36
37
38
39
40
41
42

43 We calculated adjusted ORs (aORs) by including the following covariates in the
44 logistic regression models: age, gender, Aboriginal status, prematurity, presence of
45 comorbidities, out-of-home care and household smoking. Age was included as a
46 categorical variable in the models and were divided into 6-11 months, 12-23 months,
47 2 years, 3 years and 4 years (reference group). Covariates were selected based on
48 known epidemiological or clinical risk factors for co-detection. ~~Records with missing~~
49
50
51
52
53
54
55

1
2
3
4
5
6
7 ~~data for any of the covariates were excluded from the fully adjusted models. Data~~
8 ~~from all patients were included in the adjusted models unless they had missing data~~
9 ~~on one or more covariates.~~ To investigate the impact of specific pathogen pairs,
10 analyses were repeated for the most common pathogen pairs. Estimated marginal
11 means ~~Post-hoc analysis~~ of ~~selected~~ logistic regression models ~~were~~ used to
12 calculate probabilities with 95% CIs for antibiotic prescribing and hospitalisation for
13 common pathogen pairs.
14
15
16
17
18
19
20
21

22 2.4 Ethical approvals

23
24 This study was approved by the PMH Human Research Ethics Committee
25 (1673/EP), the Western Australian Aboriginal Health Ethics Committee (212 06/08)
26 and the University of Western Australia Research Ethics Committee (RA/4/1/6456).
27
28
29
30
31

32 3 Results

33
34 Of 2715 patients recruited from 2008 to 2012, data for ~~2487-2356~~ patients were
35 available for analysis. Reasons for exclusion included incorrect or unknown age
36 (n=154, ~~67.542.9~~ % of all excluded patients), recruitment from general practice in
37 2008-2009 (n=131, 36.5%), ~~incomplete~~ pathogen testing ~~not completed~~ (n=29,
38 ~~42.78.1~~ %), unknown vaccination history (n=7, ~~3.41.9~~ %), incomplete data (n=12,
39 ~~5.33.3~~ %), multiple enrolments for the same episode of illness (n=3, ~~4.30.8~~ %), ~~or~~
40 withdrawal from the study (n=23, ~~40.16.4~~ %).
41
42
43
44
45
46
47
48

49 Of the 2356 patients enrolled, the majority (n=1848, 78.4%) were enrolled while
50 presenting to PMH emergency department. Of these 6.3% (n=117) were
51 subsequently admitted to hospital. ~~Of those included in analyses,~~ The median age
52
53
54

1
2
3
4
5
6
7 was 22.0 months (interquartile range=14.0-356.0), 554.9.2% were male and 5.67%
8 were of Aboriginal or Torres Strait Islander decent. Children born preterm accounted
9
10 for 13.35% (n=319) of patients. Children with comorbidities accounted for 15.1%
11 (n=355) of this cohort. Of those that had one or more comorbidity, asthma (n=21825,
12 62.061.4%) and other chronic respiratory conditions (n=54, 15.2%, 14.9%) were
13
14 most common.
15
16
17

Formatted: Not Highlight

18
19
20
21
22 Of 2356 patients, 52.8% (n=1244) completed questions relating to outcomes (e.g.
23 antibiotics use). Although parents were requested to complete these questions 7-10
24 days post-enrolment, yet the mean time to completion was 19.3 days and ranged
25 from 0 to 149 days (median=10 days). Data on antibiotic prescription post-enrolment
26 were available for 51.052.6% (n=~~1308~~1201) of patients, of whom 542483
27 (41.440.2%) were prescribed antibiotics. Combining data from questionnaires and
28 review of hospital records resulted in near-complete data on hospitalisation (99.4%,
29 n=2341). ~~Hospitalisation data were available for 99.0% (n=2462) of patients,~~ of
30 whom 596-610 (26.14.2%) were hospitalized. Of those who were admitted to
31 hospital, the median length of stay was 2 days (interquartile range=1-3).
32
33
34
35
36
37
38
39
40
41
42

43 Overall, 1630728 patients (69.569.2%) tested positive for a virus. Of those with at
44 least one virus detected, the most, most common were rhinovirus (n=665, 40.8%),
45 influenza (n=481, 29.5%) and RSV (n=431, 26.4%; Figure 1). Of those with at least
46 one virus detected, 24.84% (n=404) had at least one other virus co-detected
47 coinfected. Of these, 36750 (86.687.1%) had were infected with 2 viruses detected,
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 52 (12.94%) ~~had were infected with~~ 3 viruses detected and the remainder with 4 or
8 more viruses.
9

10
11
12 A greater proportion of Cchildren with multiple viruses -coinfection~~detected~~ were less
13 than 2 years old (65.4%) younger (median age=18.0 months, interquartile
14 range=12.0-29.0) and attended out of home care more compared to those with a
15 single virus infection (51.2%, p<0.001~~median age=23.0 months, interquartile~~
16 range=14.0-37.5; Table 1). Those with coinfection~~co-detection~~ also had greater
17 double the odds of presenting with cough and rhinorrhoea compared to those with
18 single infection, although both symptoms were common in both groups (Table 2).
19

20
21
22 This effect remained after adjusting for other covariates. Of note, although less
23 common, diarrhoea was more frequently observed in children with viral co-detection.
24

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
There were no significant differences in the odds of being prescribed antibiotics
(aOR=1.1, 95%CI: 0.8,1.5) or hospitalised (aOR=1.1, 95%CI: 0.8,1.4) between
patients with single infection and coinfection~~co-detection~~ (Table 2).

We then selected the three most common pathogens (rhinovirus, influenza and RSV)
and investigated associations of specific pathogen pairs with antibiotic prescription
and hospitalisation. After adjusting for other covariates, patients coinfected~~with both~~
an-influenza and /RSV pair~~detected~~ had a 528% probability (95% CI: =2833%-796%)
of being prescribed antibiotics with a trend towards more frequent prescription when
compared with those with influenza or RSV infection alone (Figure 2). Similarly, the
probability of being hospitalised was highest in those coinfected~~with influenza and~~
RSV detected (probability=554%, 95% CI: =345%-73%); significantly greater when
compared with those with influenza infection alone (probability=272%,

95%CI:156%-289%_) with a non-significant trend observed when compared with those with RSV infection alone (probability=41%, 95%CI=34%-49%). No other differences were noted when comparing coinfection and single infection with other pathogen pairs (Figure 3) and with a trend observed compared with RSV infection alone (probability=43%, 95%CI:36-51%).-

4 Discussion

This is one of the largest, single-site prospective studies of children up to 4 years of age that specifically investigates the incidence of and clinical outcomes associated with viral-viral ~~coinfection~~co-detection. Our findings demonstrate that although ~~significant~~ differences in demographics, risk factors and symptoms are identifiable, in general, viral-viral ~~coinfection~~co-detection is unlikely to be associated with more severe clinical illness among young children with influenza-like illness. However S, specific pathogen pairs may be associated with an increased probability of hospitalisation as was observed with influenza and RSV. This finding has ~~significant~~ implications in paediatric healthcare facilities where isolation of all children with acute respiratory viral infection is difficult during periods of peak respiratory virus activity and cohorting of children is frequently required prior to the availability of diagnostic test results.

We detected small differences in the symptoms presented by patients with single infection compared to those with ~~coinfection~~co-detection. However, these symptoms were common and therefore, likely to be of little clinical relevance. On the other hand, the clinical outcomes chosen (i.e. antibiotics use and hospitalisation) were more indicative of disease severity but may be subject to clinical judgement and

1
2
3
4
5
6 therefore, ~~may~~ be ~~less~~ insensitive measures of disease severity. Accordingly, we
7
8 observed no significant differences in the outcomes for children with single infection
9
10 and those with ~~coinfection~~co-detection.
11
12

13
14 This is consistent with data from previous systematic reviews, which found negligible
15
16 differences between outcomes in children and adults with ~~coinfection~~co-detection
17
18 compared to peers with single infection [18,19]. However, further analyses by
19
20 pathogen pairs suggest that some ~~virus~~ combinations of specific viral pathogens,
21
22 such as influenza and RSV, are potentially more ~~pathogenic~~significant than others.
23
24 This corroborates data from our recently completed systematic review that
25
26 specifically investigated clinical outcomes in children with ~~coinfection~~co-detection
27
28 and found no differences overall but suggest that some pathogen specific effects
29
30 may be present ~~(PROSPERO registration: CRD#42014009133)~~. [20]. Our data
31
32 suggest that future research in this area should segregate analysis by specific
33
34 pathogen pairs where numbers allow.
35

36
37 We chose to exclude bocavirus and enterovirus detections from the analyses as their
38
39 pathogenicity in ARTI is still not well-established. Bocavirus is often implicated in
40
41 both symptomatic and asymptomatic ~~coinfection~~co-detection and is thought to have
42
43 a prolonged period of shedding [6]; both features which may confound any
44
45 associations between ~~coinfection~~co-detection and clinical severity. On the other
46
47 hand, studies on the role of enteroviruses in ARTI are suggestive of pathogenicity
48
49 [21], however the numbers are small. For these reasons, detections of both viruses
50
51 were excluded from the analyses presented here. Repeat analyses including these
52
53 viruses did not change the overall findings (see Supplementary Tables 1 and 2).
54

1
2
3
4
5
6
7
8
9 An important consideration when interpreting these findings is the inability to
10 distinguish between active (and pathogenic) infection and viral shedding. Prolonged
11 viral shedding for some respiratory viruses, particularly rhinovirus, have been well-
12 documented [22,23]. Quantitative analyses may be of assistance in distinguishing
13 these clinical states yet has not become commonplace in the diagnostic laboratory
14 for respiratory viruses.

15
16
17
18
19
20
21
22 We attempted to investigate the relationship between rhinovirus infection and clinical
23 severity [22–24]. However, we were limited as we were unable to subtype
24 rhinoviruses; in particular, rhinovirus-C has been associated with greater respiratory
25 illness than subtype A [5]. Based on the proportion of patients who were hospitalised
26 with influenza and rhinovirus infections in this cohort, data from approximately 7700
27 children would have been required to provide 80% power of detecting a difference, at
28 the 0.05 level of significance, between those with a rhinovirus-C infection and those
29 with an influenza virus infection.

30
31
32
33
34
35
36
37
38
39 One limitation of our study is that only children presenting to one hospital with
40 influenza-like illness and fever were eligible for enrolment in this study.

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Consequently, it is possible that these children were at the more severe end of the
disease spectrum which may bias our results. During the course of this study, there
was a shift from using an antigen-based assay to using PCR when detecting hMPV,
although both methods were used throughout the study period. We have elected to
include detections from both methods but acknowledge that differences in the
performance of these methods would mean that potential cases of hMPV may have

1
2
3
4
5
6
7 been missed in earlier samples. These changes, as well as clinical discretion in
8 testing for hMPV, may explain the lower proportions of hMPV detections in this
9 cohort compared to other studies [24,25].

10
11
12
13
14 Further limitations of this study include missing outcomes data, particularly for
15 antibiotic prescription. In addition, data on diagnosis at discharge were not
16 collected, which may have helped to indicate the severity of symptoms. Moreover,
17
18 despite enrolling nearly 2500 children, the number of patients with infections with
19
20 specific pathogens and pathogen-pairs were relatively small.
21
22
23

24
25
26 Future studies using routinely collected, linked administrative data may assist in
27 addressing both issues. Nonetheless, this is one of the largest single-site studies
28 specifically investigating the effects of coinfection-co-detection in young children
29 using a wide panel of respiratory pathogens. Our results are similar to those reported
30 elsewhere, adding to the validity of the findings [26].
31
32
33
34
35

36
37 We conclude that the impact of coinfection-co-detection on disease severity in
38 children presenting with influenza-like illness is likely to be limited to specific
39 pathogen pairs. Therefore, routine screening for coinfection-co-detection in this
40 population should be restricted to common respiratory pathogens and efforts to
41 reduce cross infection should focus on these specific pathogens.
42
43
44
45
46
47

48 **5 Funding**

49
50 This work was supported by the Western Australia Department of Health; The
51 University of Western Australia [University Postgraduate Award to FJL]; the National
52
53
54

1
2
3
4
5
6
7 Health and Medical Research Council [APP1045668 to HCM and FJL, APP1034254
8 to HCM, [APP1111596 to CCB](#)] and the Western Australian Department of
9
10 Health/Raine Medical Research Foundation Clinician Research Fellowship to CCB.
11

12 No external funding was provided for other authors.
13
14
15

16 **6 Conflicts of interest**

17
18 None to declare.
19
20

21 **7 Acknowledgements**

22 We would like to acknowledge Peter Jacoby for his assistance with the logistic
23 regression analyses and Gabriela Willis for her assistance with cross-checking the
24 data. We would like to thank members of the Vaccine Trials Group, particularly
25
26 Christine Robins, who managed the study. We would also like to thank all the
27
28 parents and children who have participated in the WAIVE study.
29
30
31
32
33
34
35

36 **8 References**

- 37
38 1. Mahony JB. Detection of respiratory viruses by molecular methods. *Clin*
39
40 *Microbiol Rev.* **2008**;21(4):716–47.
- 41
42 2. Monto AS. Epidemiology of viral respiratory infections. *Am J Med.*
43
44 **2002**;112(Supplement 6A):4S – 12S.
- 45
46 3. Debiaggi M, Canducci F, Ceresola ER, Clementi M. The role of
47
48 infections and coinfections with newly identified and emerging
49
50 respiratory viruses in children. *Virology J.* **2012**;9.
- 51
52 4. Bialasiewicz S, Whiley DM, Lambert SB, Jacob K, Bletchly C, Wang D,
53
54

- 1
2
3
4
5
6
7 et al. Presence of the newly discovered human polyomaviruses KI and
8
9 WU in Australian patients with acute respiratory tract infection. *J Clin*
10
11 *Viol.* **2008**;41(2):63–8.
12
13 5. Linder JE, Kraft DC, Mohamed Y, Lu Z, Heil L, Tollefson S, et al. Human
14
15 rhinovirus C: Age, season, and lower respiratory illness over the past 3
16
17 decades. *J Allergy Clin Immunol.* **2013**;131(1):69–77.e6.
18
19 6. Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Söderlund-
20
21 Venermo M. Human bocavirus—the first 5 years. *Rev Med Virol.*
22
23 **2012**;22(1):46–64.
24
25 7. Aberle JH, Aberle SW, Pracher E, Hutter H-P, Kundi M, Popow-Kraupp
26
27 T. Single versus dual respiratory virus infections in hospitalized infants:
28
29 impact on clinical course of disease and interferon-[gamma] response.
30
31 *Pediatr Infect Dis J.* **2005**;24(7):605–10.
32
33 8. Peng D, Zhao D, Liu J, Wang X, Yang K, Xicheng H, et al.
34
35 Multipathogen infections in hospitalized children with acute respiratory
36
37 infections. *Virol J.* **2009**;6(155):155.
38
39 9. Kouni S, Karakitsos P, Chranioti A, Theodoridou M, Chrousos G, Michos
40
41 A. Evaluation of viral co-infections in hospitalized and non-hospitalized
42
43 children with respiratory infections using microarrays. *Clin Microbiol*
44
45 *Infect.* **2013**;19(8):772–7.
46
47 10. Martin ET, Kuypers J, Wald A, Englund JA. Multiple versus single virus
48
49 respiratory infections: viral load and clinical disease severity in
50
51 hospitalized children. *Influenza Other Respi Viruses.* **2012**;6(1):71–7.
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 11. Codde J. Rates Calculator. 9.5.5 ed. Perth, Western Australia: Health
8 Information Centre, Department of Health; **2013**.
- 9
10
11 12. Australian Bureau of Statistics. Regional Population Growth, Australia,
12 2012-13 [Internet]. Canberra; **2015** [cited 2015 Nov 13]. Available from:
13 [http://www.abs.gov.au/ausstats/abs@.nsf/Previousproducts/3218.0Feat](http://www.abs.gov.au/ausstats/abs@.nsf/Previousproducts/3218.0FeatureArticle22012-13?opendocument&tabname=Summary&prodno=3218.0&issue=2012-13&num=&view=)
14 [ure Article22012-](http://www.abs.gov.au/ausstats/abs@.nsf/Previousproducts/3218.0FeatureArticle22012-13?opendocument&tabname=Summary&prodno=3218.0&issue=2012-13&num=&view=)
15 [13?opendocument&tabname=Summary&prodno=3218.0&issue=2012-](http://www.abs.gov.au/ausstats/abs@.nsf/Previousproducts/3218.0FeatureArticle22012-13?opendocument&tabname=Summary&prodno=3218.0&issue=2012-13&num=&view=)
16 [13&num=&view=](http://www.abs.gov.au/ausstats/abs@.nsf/Previousproducts/3218.0FeatureArticle22012-13?opendocument&tabname=Summary&prodno=3218.0&issue=2012-13&num=&view=)
17
- 18
19
20
21
22
23 13. Blyth CC, Jacoby P, Effler P V, Kelly H, Smith DW, Robins C, et al.
24 Effectiveness of trivalent flu vaccine in healthy young children.
25 *Pediatrics*. **2014**;133(5):e1218–25.
- 26
27
28
29
30 14. Chidlow GR, Harnett G, Williams S, Levy A, Speers D, Smith DW.
31 Duplex real-time reverse transcriptase PCR assays for rapid detection
32 and identification of pandemic (H1N1) 2009 and seasonal influenza
33 A/H1, A/H3, and B viruses. *J Clin Microbiol*. **2010**;48(3):862–6.
- 34
35
36
37
38 15. Chidlow GR, Harnett GB, Shellam GR, Smith DW. An economical
39 tandem multiplex real-time PCR technique for the detection of a
40 comprehensive range of respiratory pathogens. *Viruses*. **2009**;1(1):42–
41 56.
- 42
43
44
45
46 16. Ireland DC, Kent J, Nicholson KG. Improved detection of rhinoviruses in
47 nasal and throat swabs by seminested RT-PCR. *J Med Virol*.
48 **1993**;40(2):96–101.
- 49
50
51
52
53 17. Juul S, Frydenberg M. EpiBasic. 2.0 ed. **2011**.
- 54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 18. Asner SA, Science ME, Tran D, Smieja M, Merglen A, Mertz D. Clinical
8 disease severity of respiratory viral co-infection versus single viral
9 infection: A systematic review and meta-analysis. PLoS One.
10
11 **2014**;9(6):e99392.
12
13
14
15 19. Goka EA, Vallely PJ, Mutton KJ, Klapper PE. Single and multiple
16 respiratory virus infections and severity of respiratory disease: a
17 systematic review. Paediatr Respir Rev. **2014**;15(4):363–70.
18
19
20
21 20. Lim FJ, de Klerk N, Blyth CC, Fathima P, Moore HC. Systematic review
22 and meta-analysis of respiratory viral coinfections in children.
23
24
25
26
27
28 21. Imamura T, Oshitani H. Global reemergence of enterovirus D68 as an
29 important pathogen for acute respiratory infections. Rev Med Virol.
30
31 **2015**;25(2):102–14.
32
33
34 22. Loeffelholz MJ, Trujillo R, Pyles RB, Miller AL, Alvarez-Fernandez P,
35 Pong DL, et al. Duration of rhinovirus shedding in the upper respiratory
36 tract in the first year of life. Pediatrics. American Academy of Pediatrics;
37
38 **2014 Dec**;134(6):1144–50.
39
40
41
42 23. Jartti T, Lehtinen P, Vuorinen T, Koskenvuo M, Ruuskanen O.
43
44 Persistence of rhinovirus and enterovirus RNA after acute respiratory
45 illness in children. J Med Virol. **2004**;72(4):695–9.
46
47
48
49 24. Fathima S, Lee B, May-Hadford J, Mukhi S, Drews S. Use of an
50
51 Innovative Web-Based Laboratory Surveillance Platform to Analyze
52
53 Mixed Infections Between Human Metapneumovirus (hMPV) and Other
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 Respiratory Viruses Circulating in Alberta (AB), Canada (2009–2012).
8
9 Viruses. Molecular Diversity Preservation International; **2012 Nov**
10
11 **5**;4(11):2754–65.
12
13 25. Ali SA, Williams J V, Chen Q, Faori S, Shehabi A, Al Jundi E, et al.
14
15 Human metapneumovirus in hospitalized children in Amman, Jordan. J
16
17 Med Virol. **2010**;82(6):1012–6.
18
19 26. Dierig A, Heron LG, Lambert SB, Yin JK, Leask J, Chow MYK, et al.
20
21 Epidemiology of respiratory viral infections in children enrolled in a study
22
23 of influenza vaccine effectiveness. Influenza Other Respi Viruses.
24
25 **2014**;8(3):293–301.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 **9 Tables**

8
9 **9.1 Table 1 – Cohort characteristics by infection status**

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Description	Frequency (n= 24872356)								
	No pathogen (n= 726759)			Single infection (n= 12264307)			CoinfectionCo-detection (n= 404424)		
	n	%	(95% CI)	n	%	(95% CI)	n	%	(95% CI)
Aged less than 2 years	382392	52.62	(48.91-48.03-51.65 55.26)56.30)	6286	51.225	(48.38-54.06)(48.67-54.16)	264	65.356	(60.48-69.98)(59.59-68.95)
Male	397414	54.68	(50.98-54.55 58.35(50.93-58.13))	6687	54.495	(51.65-57.30)(52.11-57.58)	228	56.445	(51.44-61.33)(52.36-62.02)
Aboriginal or Torres Strait Islander <u>descent-descent</u>	3334	4.554	(3.12-6.20)(3.15-6.32)	7174	5.795	(4.55-7.25)(4.47-7.06)	313	7.677	(5.27-10.71)(5.06-10.29)
Born preterm	102406	14.05	(11.60-	1584	12.894	(11.06-	596	14.604	(11.31-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

		13.97	16.79(11.58-	65	2.62	14.89)(10.87-	0	4.25	18.43)(11.06-
			16.64))			14.55)			17.96)
One or more comorbidities	117418	<u>16.12</u>	<u>(13.51-</u>	<u>1834</u>	<u>14.934</u>	<u>(12.98-</u>	<u>555</u>	<u>13.614</u>	<u>(10.42-</u>
		15.55	19.00)(13.04-	89	4.46	17.05)(12.60-	6	3.30	17.35)(10.21-
			18.32))			16.49)			16.92)
More than 4 hours in out-of-home care	442459	<u>60.88</u>	<u>(57.22-</u>	<u>8258</u>	<u>67.296</u>	<u>(64.59-</u>	<u>299</u>	<u>74.017</u>	<u>(69.44-</u>
		60.47	64.45)(56.90-	72	6.72	69.91)(64.09-	307	2.92	78.22)(68.41-
			63.97))			69.27)			77.11)
Smoking in household	154165	<u>21.21</u>	<u>(18.29-</u>	<u>2833</u>	<u>23.082</u>	<u>(20.75-</u>	<u>107</u>	<u>26.492</u>	<u>(22.24-</u>
		21.74	24.37)(18.85-	95	3.34	25.55)(21.07-	110	6.13	31.07)(21.99-
			24.85))			25.73)			30.60)
Influenza vaccine on year of admission	188213	<u>25.90</u>	<u>(22.74-</u>	<u>3033</u>	<u>24.712</u>	<u>(22.32-</u>	<u>100</u>	<u>24.752</u>	<u>(20.62-</u>
		28.06	29.24)(24.89-	64	7.85	27.23)(25.43-	111	6.37	29.26)(22.22-
			31.41))			30.37)			30.85)

4

5 Note: CI=Confidence Intervals. Exact 95% CI presented. Denominators include cases with missing data. Detections of enterovirus

6 or bocavirus were ignored in counts of single and ~~coinfection~~co-detection.

9.2 Table 2 – Frequency and logistic regression models of symptoms and outcomes by infection type

Description	Frequency		Logistic regression models	
	Single infection (n=1226) % (95% CI)	Co-detection (n=404) % (95% CI)	Co-detection OR ^a (95% CI)	Co-detection aOR (95% CI) <i>a,ba</i>
Symptoms				
Cough	88.66 (86.75-90.38)	93.32 (90.43-95.55)	<u>1.95</u> (1.24-3.06)	<u>1.94</u> (1.21-3.13)
Rhinorrhoea	88.09 (86.15-89.85)	93.32 (90.43-95.55)	<u>2.07</u> (1.32-3.23)	<u>1.79</u> (1.12-2.85)
Wheezing	43.56 (40.76-46.39)	49.01 (44.03-54.00)	<u>1.26</u> (1.01-1.58)	<u>1.20</u> (0.94-1.52)
Dyspnoea	45.84 (43.02-48.68)	50.74 (45.75-55.72)	<u>1.23</u> (0.98-1.55)	<u>1.15</u> (0.91-1.47)
Rash	17.86 (15.76-20.12)	14.11 (10.86-17.89)	<u>0.75</u> (0.55-1.03)	<u>0.69</u> (0.49-0.95)
Diarrhoea	20.39 (18.17-22.76)	27.23 (22.94-31.85)	<u>1.47</u> (1.13-1.90)	<u>1.33</u> (1.01-1.74)
Vomiting	38.58 (35.85-41.37)	42.82 (37.94-47.81)	<u>1.19</u> (0.94-1.50)	<u>1.16</u> (0.91-1.48)
At least 1 symptom	97.55 (96.53-98.34)	99.26 (97.85-99.85)		
Outcomes				
Antibiotics given ^{cb}	19.98 (17.78-22.33)	21.53 (17.62-25.87)	<u>1.19</u> (0.86-1.63)	<u>1.11</u> (0.79-1.54)

Admitted to hospital	23.98 <u>24.55</u> (21.61-26.47 <u>22.16-27.06</u>)	26.24 (22.01-30.82)	<u>1.13</u> (<u>0.87-1.46</u>)	<u>1.09</u> (<u>0.83-1.44</u>)
----------------------	---	---------------------	----------------------------------	----------------------------------

Note: CI=confidence intervals. Denominators include those with missing data. The number of children with missing data are as follows: cough (n=4 for single infection; n=3 for co-detection), rhinorrhoea (n=4; n=3), wheezing (n=4; n=4), dyspnoea (n=5; n=4), rash (n=30; n=9), diarrhoea (n=30; n=10), vomiting (n=32; n=9), antibiotics given (n=587; n=199), admitted to hospital (n=6; n=2).

Infections with either enterovirus or bocavirus were ignored in counts of single infection and ~~coinfection~~ co-detection.

~~Adjusted models were adjusted for age, gender, Aboriginal status, preterm birth, presence of comorbidities, out-of-home care and household smoking. Models presented are the odds of having a symptom/outcome in children with coinfection compared with children with single infection.~~

^a Models presented are the odds of having a symptom/outcome in children with co-detection compared with children with single infection.

^b Models were adjusted for age, gender, Aboriginal status, preterm birth, presence of comorbidities, out-of-home care and household smoking. All covariates listed were inputted as categorical variables.

^{ac} Data were only available for ~~706-639~~ children with single infection and ~~219-205~~ children with ~~coinfection~~ co-detection.

Formatted: Highlight

1
2
3
4
5
6
7 22 **10 Figure legends**
8

9 23 Figure 1 – Frequency of pathogen detection and ~~coinfection~~co-detection
10

11 24 Figure 2 – Probability of post-enrolment ~~use of~~ antibiotics use by pathogen pairs with 95%
12 confidence intervals
13 25

14
15 26 Figure 3 - Probability of hospitalisation by pathogen pairs with 95% confidence intervals
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Review Only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

27 **11 Figures**


28 **11.1 Figure 1 – Frequency of pathogen detection and ~~coinfection~~co-detection**

For Review Only

Formatted: Font: 12 pt, Not Bold




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49



Note: RSV=respiratory syncytial virus, hMPV = human metapneumovirus. Detection of enterovirus and bocavirus were excluded from subsequent analyses.

33 11.2 Figure 2 – Probability of use of post-enrolment antibiotics use -by pathogen pairs with 95% confidence intervals




Formatted: Font: 12 pt, Not Bold

34

32

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49




Formatted: Font: 12 pt, Not Bold

Note: RSV=respiratory syncytial virus.

33

37 **11.3 Figure 3 – Probability of hospitalisation by pathogen pairs with 95% confidence intervals**




Formatted: Font: 12 pt, Not Bold

38

34

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49



Formatted: Font: 12 pt, Not Bold

Note: RSV=respiratory syncytial virus.

Supplementary Table 1 – Cohort characteristics by infection status (all viruses included)

Description	Frequency (n=23562487)								
	No pathogen (n=542573)			Single infection (n=12284309)			Co-detection infection (n=586605)		
	n	%	(95% CI)	n	%	(95% CI)	n	%	(95% CI)
Aged less than 2 years	279288	51.485	(47.18-55.76)	6116	49.764	(46.91-52.59)	384	65.53	(61.52-69.38)
		0.26	(46.09-54.43)	54	9.96	(47.22-52.71)	393	64.96	(61.01-68.76)
Male	293340	54.065	(49.76-58.31)	6647	54.075	(51.24-56.89)	336	57.34	(53.22-61.38)
		4.40	(49.92-58.24)	42	4.39	(51.65-57.12)	350	57.85	(53.80-61.82)
Aboriginal or Torres Strait Islander descent	2627	4.804	(3.16-6.95)	7275	5.865	(4.62-7.33)	373	6.316	(4.48-8.60)
			(3.13-6.78)			(4.53-7.13)			(4.34-8.33)
Born preterm	7074	12.924	(10.21-16.03)	1634	13.274	(11.42-15.30)	868	14.68	(11.91-17.80)
		2.94	(10.28-16.03)	69	2.94	(11.14-15.30)	8	14.55	(11.88-17.80)

Formatted Table

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

			45.94)			44.85)			47.61)
Has 1 or more comorbidities	<u>9293</u>	<u>16.974</u>	(<u>13.91-</u>	<u>1864</u>	<u>15.154</u>	(<u>13.19-</u>	<u>777</u>	<u>13.14</u>	(<u>10.51-</u>
		<u>6.23</u>	<u>20.40)</u> (<u>13.30-</u>	<u>92</u>	<u>4.67</u>	<u>17.28)</u> (<u>12.79-</u>	<u>8</u>	<u>12.89</u>	<u>16.15)</u> (<u>10.33-</u>
			<u>49.51)</u>			<u>46.70)</u>			<u>45.83)</u>
More than 4 hours in out-of-home care	<u>346364</u>	<u>63.846</u>	(<u>59.63-</u>	<u>8128</u>	<u>66.126</u>	(<u>63.40-</u>	<u>408</u>	<u>69.62</u>	(<u>65.72-</u>
		<u>3.00</u>	<u>67.89)</u> (<u>58.90-</u>	<u>64</u>	<u>5.78</u>	<u>68.77)</u> (<u>63.13-</u>	<u>416</u>	<u>68.76</u>	<u>73.33)</u> (<u>64.90-</u>
			<u>66.97)</u>			<u>68.35)</u>			<u>72.43)</u>
Has smoking in household	<u>119430</u>	<u>21.962</u>	(<u>18.54-</u>	<u>2823</u>	<u>22.962</u>	(<u>20.64-</u>	<u>143</u>	<u>24.40</u>	(<u>20.98-</u>
		<u>2.69</u>	<u>25.68)</u> (<u>19.32-</u>	<u>04</u>	<u>3.22</u>	<u>25.42)</u> (<u>20.96-</u>	<u>146</u>	<u>24.13</u>	<u>28.09)</u> (<u>20.77-</u>
			<u>26.34)</u>			<u>25.61)</u>			<u>27.75)</u>
Had influenza vaccine on year of admission	<u>150474</u>	<u>27.683</u>	(<u>23.95-</u>	<u>3063</u>	<u>24.922</u>	(<u>22.52-</u>	<u>135</u>	<u>23.04</u>	(<u>19.69-</u>
		<u>0.37</u>	<u>31.65)</u> (<u>26.62-</u>	<u>66</u>	<u>7.96</u>	<u>27.44)</u> (<u>25.54-</u>	<u>148</u>	<u>24.46</u>	<u>26.66)</u> (<u>21.09-</u>
			<u>34.31)</u>			<u>30.48)</u>			<u>28.09)</u>

Note: CI=Confidence Intervals. Exact 95% CI presented. Denominators include cases with missing data.

Supplementary Table 2 – Frequency and logistic regression models of symptoms and outcomes by infection type (all viruses)

Description	Frequency		Logistic regression models	
	Single infection (n=13091228) % (95% CI)	Co-detectioninfection (n=605586) % (95% CI)	Co-detectionCoinfection OR ^a (95% CI)	Co-detectionCoinfection aOR ^{a,b} (95% CI)
Symptoms				
Cough	87.8787.55 (85.91-89.64)(85.64-89.29)	91.4791.24 (88.91-93.60)(88.70-93.37)	1.531.54 (1.09-2.16)(1.10-2.16)	1.631.65 (1.12-2.36)(1.15-2.37)
Rhinorrhoea	86.6486.78 (84.61-88.50)(84.83-88.57)	92.3292.40 (89.86-94.34)(89.99-94.38)	1.941.96 (1.36-2.76)(1.37-2.79)	1.721.75 (1.18-2.51)(1.21-2.54)
Wheezing	43.0842.63 (40.29-45.90)(39.93-45.36)	48.6347.93 (44.52-52.77)(43.89-52.00)	1.261.25 (1.03-1.54)(1.03-1.52)	1.231.22 (0.99-1.53)(0.99-1.50)
Dyspnoea	44.8744.23 (42.06-47.70)(41.52-47.06)	51.1950.25 (47.06-52.00)	1.301.28 (1.07-1.52)	1.271.24 (1.03-1.50)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

		46.97)		55.31)(46.19-		1.58)(1.05-		1.57)(1.04-
				54.31)		4.55)		4.53)
Rash	<u>17.59</u> <u>17.34</u>	<u>(15.50-19.84)</u> <u>(15.33-</u>	<u>15.70</u> <u>15.37</u>	<u>(12.85-</u>	<u>0.87</u> <u>0.86</u>	<u>(0.66-</u>	<u>0.82</u> <u>0.81</u>	<u>(0.62-</u>
		49.50)		18.90)(12.59-		1.13)(0.66-		1.08)(0.62-
				18.50)		4.12)		4.07)
Diarrhoea	<u>19.95</u> <u>20.63</u>	<u>(17.75-22.30)</u> <u>(18.46-</u>	<u>24.57</u> <u>24.46</u>	<u>(21.14-</u>	<u>1.31</u> <u>1.24</u>	<u>(1.03-</u>	<u>1.17</u> <u>1.11</u>	<u>(0.91-</u>
		22.96)		28.27)(21.07-		1.65)(0.99-		1.50)(0.87-
				28.09)		4.56)		4.41)
Vomiting	<u>38.93</u> <u>38.35</u>	<u>(36.19-41.72)</u> <u>(35.71-</u>	<u>40.44</u> <u>40.66</u>	<u>(36.44-</u>	<u>1.06</u> <u>1.10</u>	<u>(0.86-</u>	<u>1.03</u> <u>1.07</u>	<u>(0.84-</u>
		41.05)		44.54)(36.72-		1.29)(0.90-		1.28)(0.87-
				44.70)		4.34)		4.32)
Outcomes								
Antibiotics given ^c	<u>19.71</u> <u>24.62</u>	<u>(17.52-22.04)</u> <u>(19.42-</u>	<u>20.99</u> <u>24.65</u>	<u>(17.76-</u>	<u>1.09</u> <u>1.04</u>	<u>(0.82-</u>	<u>0.98</u> <u>0.92</u>	<u>(0.73-</u>
		23.95)		24.51)(18.43-		1.44)(0.77-		1.31)(0.70-
				25.15)		4.33)		4.22)
Admitted to hospital	<u>24.35</u> <u>22.31</u>	<u>(21.97-26.85)</u> <u>(20.08-</u>	<u>28.16</u> <u>27.11</u>	<u>(24.55-</u>	<u>1.22</u> <u>1.29</u>	<u>(0.97-</u>	<u>1.18</u> <u>1.25</u>	<u>(0.92-</u>
		24.66)		31.99)(23.60-		1.52)(1.03-		1.49)(0.98-

30.84)

1.61)

1.58)

Note: CI=confidence intervals. Denominators include those with missing data. The number of children with missing data are as follows: cough (n=4 for single infection; n=3 for co-detection), rhinorrhoea (n=4; n=3), wheezing (n=4; n=4), dyspnoea (n=5; n=4), rash (n=32; n=13), diarrhoea (n=33; n=14), vomiting (n=34; n=13), antibiotics given (n=601; n=283), admitted to hospital (n=6; n=2).

^a Models presented are the odds of having a symptom/outcome in children with co-detection compared with children with single infection.

^b Models were adjusted for age, gender, Aboriginal status, preterm birth, presence of comorbidities, out-of-home care and household smoking.

All covariates listed were inputted as categorical variables.

^c Data were only available for 627 children with single infection and 283 children with co-detection.

~~Adjusted models were adjusted for age, gender, Aboriginal status, preterm birth, presence of comorbidities, out-of-home care and household smoking. Models presented are the odds of having a symptom/outcome in children with coinfection compared with children with single infection.~~

~~^a Data were only available for 694 cases with single infection and 319 cases with coinfection.~~